ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  1 of 62  
  
 
 
 
 
 
Phase I/II Study of Everolimus  and Intravesical Gemcitabine  in BCG -Refracto ry 
Prima ry or Seconda ry Carcinoma In Situ of the Bla dder  
MSKCC THERA PEUTIC/DIAGNOSTIC  PRO TOCOL  
 
 
Principal  Investigator/D epartment:  Guido  Dalbagni,  MD Department  of Surgery, 
Urology  Service  
Co-Principal  
Investigator(s)/Departm ent: Matthew  I. Milowsky,  MD 
 
Dean  F. Bajorin,  MD Department  of Medicine, 
Genitourinary  Service 
Department  of Medicine, 
Genitourinary  Service  
Investigator(s)/Departm ent: Bernard  Bochner,  MD 
 
S. Machele Donat,  MD 
Jonathan Coleman,  MD 
Vincent  Laudone,  MD 
Paul Russo,  MD 
Harry  Herr,  MD 
 
Jaspreet  S. Sandhu,  MD 
Andrew  Vickers, PhD 
Hikmat  Al-Ahmadie,  MD 
Marcia  Kalin,  MD 
Rana  Kaplan,  MD Department  of Surgery, 
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Surgery,  
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of 
Epidemiology -Biostatistics 
Department  of Pathology 
Department  of Medicine, 
Endocrinol ogy Service 
Department  of Medicine, 
Pulmonary  Service  
Consenting  Professional(s)/Department:  Guido  Dalbagni,  MD 
 
Bernard Bochner,  MD 
S. Machele Donat,  MD 
Jonathan Coleman,  MD 
Vincent  Laudone,  MD Department  of Surgery, 
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Surgery,  
Urology  Service 
Department  of Surgery,  
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  2 of 62  
  
Paul Russo,  MD 
 
Jaspreet  S. Sandhu,  MD 
Matthew  I. Milowsky,  MD 
Dean  F. Bajorin,  MD Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Surgery, 
Urology  Service 
Department  of Medicine, 
Genitourinary  Service 
Department  of Medicine, 
Genitourinary  Service  
 
 
 
 
Please Note :  A Cons enting  Profe ssional  must  have  completed  the mandatory  Human  
Subjects Education  and Certification  Progr am. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Memorial  Sloan-Kettering  Cancer  Center  
1275  York Avenue  
Ne w York,  New York 10065 
 
 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  3 of 62  
 Table of Contents  
 
1.0 PRO TOCOL  SUMM ARY  AND/OR SCH EMA ................................................................................4  
2.0 OBJECTIVES AND SCIENTIFIC  AIMS ........................................................................................ .5 
3.0 BACKGROUND AND RATIONA LE ..............................................................................................6  
3.1 mTOR  Path way and Mechanism  of Action  .................................................................... 6 
3.2 Preclinical Studies  ...................................................................................................... ..... 8 
3.2.1  Precli nical Safety  ................................................................................................. 9 
3.3 Clinical Experience  ..........................................................................................................  9 
3.3.1  Everolimus  Pharmacokinetic s.............................................................................. 9 
3.3.2  Everolimus  Pharmacodynamic  Studies  .............................................................  10 
3.3.3  Clinic al Experience with Everoli mus  ..................................................................  10 
3.4 Gemcitabine  .............................................................................................................. ......12 
3.4.1  Precli nical Studi es with Intravesical Gemci tabine ..............................................  13 
3.4.2  Clinic al Experience with Intravesical  Gemci tabine ............................................  13 
3.5 Carcinoma  In Situ (0is)...................................................................................................15  
3.5.1  Natural  History  of Bladder  Cancer  ..................................................................... 15 
3.5.2  Recurrence ........................................................................................................ 16 
3.5.3  Progression ........................................................................................................ 16 
3.5.4  Current  Concepts  in Intravesical Therapy  .........................................................  16 
3.6 Rationale  for this Study .................................................................................................18  
 
4.0 OVERVIEW  OF STUDY  DESIGN/INTERV ENTION .................................................................... 18 
4.1 Desig n..............................................................................................................................18  
4.1.2  Proposed Correlative  Studies  ............................................................................ 20 
4.2 Intervention  .................................................................................................................. ...21 
 
5.0 THERAPEUTIC/DIAGNOSTIC AGENTS  ....................................................................................21  
5.1 Everolimu s.............................................................................................................. ........ 21 
5.1.1  D rug  Dispensing/ Adm inistration  ........................................................................ 21 
5.1.2  Storage  and Stabilit y.......................................................................................... 22 
5.1.3  Source of Drug................................................................................................... 22 
5.1.4  Drug Accountability  ............................................................................................ 22 
5.1.5  Toxici ty............................................................................................................... 22 
5.2 Ge mcitabine  .............................................................................................................. ..... 23 
5.2.1  Investigational  Drug Descripti on ........................................................................ 23 
5.2.2  Availability  .......................................................................................................... 23 
5.2.3  Administration  .................................................................................................... 23 
5.2.4  Toxici ty............................................................................................................... 23 
 
6.0 CRITERIA FOR  SUBJECT ELIG IBILITY  ....................................................................................23  
6.1 Subject  Inclusion  Criteria  .............................................................................................. 23 
6.2 Subject  Exclusion  Criteria  ............................................................................................. 25 
 
7.0 RECRUITMENT  PLAN................................................................................................................ .26 
8.0 PRETREA TMENT  EVALUATIO N................................................................................................26  
9.0 TREA TMENT/INTERVENTION  PLAN  ......................................................................................... 27 
9.1 Phase  I Schedule  and Dose  Administration  ................................................................ 28 
9.1.1  Dose  Escalation Scheme................................................................................... 28 
9.1.2  Maximum Tolerated Dose.................................................................................. 29 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  4 of 62  
 9.2 Phase  II Dose  Administration  ....................................................................................... 29 
9.2.1  Interruption or Discontinuation of Treatment  During Phase II ............................ 29 
9.3 Dose  Modification  ..........................................................................................................  30 
9.3.1  Monitoring of Everolimus  Suspected Toxicities  .................................................  32 
9.3.2  Management  of Stomatitis/Oral  Mucositis /Mouth  Ulc er s  ...................................  32 
9.3.3  Management  of Hyperlipidemia  and Hy p er glycem ia  .........................................  32 
9.3.4  Management  of Non- Infectious  Pneumonitis  .....................................................  33 
9.3.5  Management  of Hepatitis  B ............................................................................... 34 
9.3.6  Management  of Hepatitis  C ............................................................................... 36 
9.4 Concomitant  Thera py .................................................................................................... 36 
 
10.0 EVALUATION  DURING  TREATMENT/ INTERVENTION  ..........................................................39  
11.0 TOXIC ITIES/SIDE EFFECT S.....................................................................................................45  
11.1 Known Undesirable  Side Effects  of Everolimus  .......................................................  45 
12.0 CRITERIA  FOR  THERAPEU TIC RESPONSE/OU TCOME  ASSESSMENT  ............................  47 
 
13.0 CRITERIA  FOR  REMOVAL  FROM  STUDY  .............................................................................. 47 
14.0 BIOS TATISTICS  ........................................................................................................... ............. 47 
15.0 RESEARCH  PARTICIPANT  REGIS TRATION  AND RANDOMI ZATION  PROCEDURES  .......49 
15.1 Re search  Participant  Registration  ..............................................................................49  
15.2 Randomization  .............................................................................................................. 49 
 
16.0 DATA M ANAGEM ENT  ISSUES  ................................................................................................49  
16.1 Quality  Assurance  ........................................................................................................50  
16.2 Data  and Safety  Monitoring  .........................................................................................50  
 
17.0 PRO TECTION  OF HUM AN  SUBJEC TS ................................................................................... 50 
17.1 Privacy  ................................................................................................................. .......... 50 
17.2 Se rious  Adverse  Event  (SAE)  Reportin g.................................................................... 51 
17.2.1 Serious  Adverse Event  (SAE)  Reporting to Novartis  ...................................... .51 
 
18.0 INFORM ED  CON SENT PROCEDURES  ................................................................................... 52 
18.1 Re search  Authorization  ...............................................................................................53  
19.0 REFERENCES  ........................................................................................................................... 53 
 
20.0 APPENDICES  .............................................................................................................. .............. 57 
 
 
1.0PROTOCOL  SUMMARY AND/OR SCHEMA  
 
This is a Phase  I/II trial of Everolim us in combi nation  with intravesical  gemcitabine  in patients  with 
BCG -refrac tory TisN0M0.  
 
Phase  I: We will evaluate 3 dose levels  of contin uous  Everolimus  (Everol imus dose le vels: Dose 
level 1: 5 mg every  other day, Dose  level 2: 5 mg daily,  and Dose  level 3: 10 mg daily)  in 
combination with a fixed dose  of intravesical  gemcitabine at a dose  of 2000 mg twice  weekly  for 3 
weeks, followed by a we ek of rest from gemcitabine— this constitutes  one 28-day cycle— and a 
second course of intravesical  gemci tabine followed by a week of rest from gemcitabine.  Everolimus  
will be continued for 12 months  in the patients  who achieve a CR. 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  5 of 62  
  
Agent Cycle 1 
(Weeks  +2 days) Cycle 2 
(Weeks  +2 days) Cycles 3-12 
(+7 days)  
1 2 3 4* 5 6 7 8*  
Gemcitabine X X X  X X X   
Eve r olim us  X X X X X X X X  
*One  w eek of  rest from intravesical  ge mc i t abine. There is no w eek of  rest from Everoli mus, w hich is ta ken continuously. 
 
Phase  II: Patients  will receive continuous  Everolimus  administered at the dose  deter mined  from the 
Phase  I part of the study  and intravesical  gemci tabine at a dose of 2000  mg twice  weekly for 3 
weeks  followed by a we ek of rest from gemcitabine —this  constitutes  one 28-day cycle—and  a 
second course of intravesical  gemci tabine followed by a week of rest from gemcitabine.  Everolimus 
will be continued for 12 months  in the patients  who achieve a CR. Patients  demonstrating a CR (by 
cystoscopy and cytology) will be observed with serial  cystoscopies  every 3 months.  
 
 
Agent Cycle 1 
(Weeks  +2 days) Cycle 2 
(Weeks  +2 days) Cycles 3-12 
(+7 days)  
1 2 3 4* 5 6 7 8*  
Gemcitabine X X X  X X X   
Eve r olim us  X X X X X X X X  
*One  w eek of  rest from intravesical  ge mc i t abine. There is no w eek of  rest from Everoli mus, w hich is ta ken continuously. 
 
 
 
 
2.0OBJECTIVES AND SCIENTIFIC  AIMS  
 
Primary  
 
The primary  endpoints  are: 
 
a.) Phase I - to establish  the dose- limiting  toxicity  (DLT)  and the maximum tolerated dose (MTD)  
of Everolim us given  in conjunction with intravesical gemcitabine.  
b.) Phase II - to determine the proporti on of patients  who are free of disease at 1 year following 
start of therapy. 
 
Secon dary  
 
The second ary endpoints  are: 
 
a.) To determine  the CR rate (by cytology and cystoscopy)  in patients  receiving Everol imus in 
combination with intravesical gemci tabine.  
b.) To determine  the survival of patients treated  with Everolim us in combi nation with intravesical 
gemcitabine.  
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  6 of 62  
 c.) To evaluate for activated mTOR  pathway  markers  as well as PTEN  status  and AKT 
activation in all pretreatment  specime ns and analysis  of posttreatment  specimens  when  
available . 
 
 
 
3.0BACKGROUND AND RATIONALE  
 
Everolimus  is a novel  oral derivative  of rapamycin.  
 
Everolimus  has been  in clinical  development  since 1996  as an immuno suppressant  in solid organ 
transplantation and has obtained marketing authorization (C ertica n®) for prophylaxis  of rejection in 
renal  and cardiac transplantation in a number  of countries,  including the majority  of the European 
Union.  Everolimus  has been  in development  for patients  with various  malignanci es since  2002.  
 
Everolimus  is being investigated  as an anticancer  agent  based  on its potential  to act: 
 
• Directly  on the tumor  cells by inhibiting  tumor  cell growth  and proliferation  
 
• Indirectly  by inhibiting a ngiogenesis,  leading  to reduced  tumor  vascularity (via potent  inhibition of 
tumor  cell HIF-1 activity, vascular en dothelial  growth factor  (VEGF)  production,  and VEGF - 
induced proliferation of endothelial  cells).  The role of angiog enesis  in the maintenance of solid 
tumor  growth is well established,  and the mammalian  target  of rapamyc in (mTOR)  pathway  has 
been  implicated  in the regulation of tumor  production of proangiogenic  factors as well as 
modulation of VEGFR  signaling in endothelial  cells.  
 
At weekly  and daily schedules  and at various  doses  explo red, Everolimus  is gener ally well tolerated. 
The most  frequent  adverse events  (rash,  mucos itis, fatigue,  and headache)  associat ed with 
Everolimus  therapy  are manageable.  Noninfect ious pneumonitis  has been reported with mTOR 
inhibitors,  but is commonly  low grade  and reversible.  
 
 
3.1 mTOR  Path way and Mechanism  of Action  
 
At the cellular  and molecular  levels,  Everolimus  acts as a sig nal transduction inhibit or. Everolimus 
selectively  inhibits  mTOR,  a key and highly  conservative serine- threonine  kinase,  which is present in 
all cells and is a centr al regulator  of protein synthesis and ultimately  cell growth,  cell proliferation, 
angiogenesis,  and cell survival. mT OR is the only currently  known target  of Everolimus.(1)  
 
mTOR  is downstream  of the PI3K/AKT  pathway, a pathway  known to be dysregulated in a wide 
spectrum  of human  cancers (e.g., through loss/m utation of the PTEN  negative  regulator,  through 
PI3K mutat ion/amplification,  through AKT/PKB overexpression/overactivation,  and through 
modulation of tuberous  sclerosis co mplex  1 and 2 (TSC1/TSC2)  tumor  suppressors).  In addition, 
activation of the PI3K/AKT/mTOR  pathway  is frequently  a characteristic  of worseni ng prognosis 
through  increased aggressiveness, r esistance to treatment,  and progression.  
 
The main known functions of  mTOR  include the following (1- 2): 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  7 of 62  
 • mTOR  functions  as a se nsor of mitogens,  growth factors, and energy  and nutrient  levels, 
facilita ting cell-cycle progression from G1 to S phase  in appropriate growth  condition s. 
• The PI3K/mTOR  pathway  itself is frequently  activated in many  human  cancers, and oncogenic 
transformation may sensitize tumor  cells to mTOR inhibitors.  
• Through the inactivation of the eukar yotic transl ation initiation factor  (elf)4E- binding proteins  (4E- 
BP1)  and activation  of the 40S ribosomal  S6 kinases (i.e., p 70S6K1),  mTOR  regulates  the 
translation of important  messages, including those encoding the HIF-1 proteins,  c-myc, ornithine 
decarboxylase,  and cyclin D1, as well as riboso mal proteins  themselves.  
• The activation  of the mT OR  pathway  leads  to the increas ed production  of proangi ogenic  factors 
(i.e., VEGF)  in tumors  and to tumor,  endothelial,  and smooth muscle cell growth  and 
proliferation.  
• The regulation of mTOR  signaling  is complex  and involves  positive  regulators,  such as AKT that 
phosphorylate and inactivate  negative regulators  such as the TSC1/TSC 2. 
 
 
 
mTOR  is represented by 2 structurally  and function ally distinct multiprot ein signaling  complexes, 
mTOR  complex  1 (mTORC1,  rapamycin sensiti ve) and mT OR  complex  2 (mTORC2,  rapamycin 
insensi tive).(3)  
 
mTORC1  is mainly  activated  via the PI3 kinase pathway  through AKT (also  known  as PKB,  protein 
kinase B) and the TSC1/TSC2.(2)  Activated AKT phosphorylates  TSC2,  which  lead to the 
dissociation  of the TSC1/TSC2  complex,  thus inhibiting the ability of TSC2  to act as a GTPase - 
activating pr otein.  This allows Rheb,  a small  G-protein,  to remain in a GTP-bound state and to 
activate mTORC1.  AKT can also activate  mTORC1  by phosphorylation of proline -rich AKT substrate 
of 40 kilodaltons (PRAS40),  thereby  relieving the PRAS40 -mediated inhibition  of mTORC1.(4 -5) 
 
mTORC2  is activated through a currently unknown me chanism,  possibly  by receptor  tyrosine  kinase 
(RTK)  signaling.(4)  It has been  sugg ested that mTORC2  phos phorylates  and activates  a different 
pool of AKT that is not upstream  of mTORC1.  PH domain leucine -rich repeat protein phosphatase 
(PHLPP)  plays a role of a negative regulator.  mTORC2  is rapamycin insensitive and is required f or 
the organiz ation of the actin  cytoske leton.(3)  
 
mTORC1 -mediated  signaling is subject  to modulation by the macrocyclic lactone  rapamycin and its 
derivatives,  such as Everolimus.  Once  these ag ents bind to the 12 kDa cytosolic FK 506-binding 
protein  12 (FKBP12),  an immunop hilin, the resulting rapamycin- FKBP12  complexes  bind to a 
specific  site near the catalytic  domain  of mT O RC1 and inhibit  phospho rylation of mTOR  substrates. 
As a conseq uence,  downstream  signaling  events  involved  in regulation of the G1 to S-phase 
transition are inhibited.  This mechanism  is thought to be responsible for the immun osuppressive 
effects  of rapamycin as well as its putative  antineoplastic  activity.(6) As many  cancers  are 
characteriz ed by dysreg ulation of G1 transit  (e.g., overexpr ession of cyclin  or cyclin- dependent 
kinases),  inhibition  of mTOR becomes  an intriguing target  for inducing cytostasis.(2) 
 
 
3.2 Preclinical Studies  
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  8 of 62  
  
 
Preclinic al investigatio ns have demonstrated th at Everolim us is a potent  inhibitor  of the proliferation 
of a range  of human tumor  cell lines in vitro, with IC50s rangi ng from sub/low  nanomol ar (nM) to µM 
concentrati ons, concent rations  capa ble of being  reached in patients  at the doses  used in clinical 
trials.  
 
Everolimus  was shown  to have activity  in human  tumor  cell lines originating from lung,  breast, 
prostate,  colon,  kidney,  melanoma,  and glioblas toma.  Everolimus  was also shown to have  activity  in 
human  pancreatic  neuroendocrine  cells,  where  induction  of apoptosis  was reported, (7) as well as in 
acute  myeloid  leukemia  cells,(8)  adult T-cell leukemia  cells, (9) diffuse  large B-cell lymphoma cel ls 
(DLBCL),( 10) pancreatic  tumor  cells,(11)  ovarian cancer  cells,(12 -13) and hepatoc ellular carcinoma 
cells.(14)  
 
As a single  agent,  Everolimus  inhibited proliferation in 3 mantle cell lymphoma cell lines (Jeko1, 
SP49,  and NCEB1)  approximately  40% to 65% compared  to control  cells. This was associat ed with 
G1 cell-cycle arrest  and reduced ph osphorylation of the mT OR  downstream  target,  4E-BP1.(15)  
 
In a clonoge nic assay  using  cells from 81 patient -derived tumor  xenografts  never  cultured in vitro (11 
human  tumor types,  with 3 to 24 tumors  each:  bladder,  colon, gastric,  non- small  cell lung cancer 
(NSCLC)  [adeno,  squamous  epithelium,  and large cell], small  cell lung cancer  (SCLC),  breast, 
ovarian,  pancreatic,  renal, melanom a, and pleur amesothelioma),  Everolimus  inhibit ed colony 
formation  in a concentrat ion-depende nt manner.  In addition,  normal  hemat opoietic  stem cells were 
insensi tive to Everolim us, with an IC50 about  15-fold higher  than the tumor  lines.  
 
Everolimus  also inhibits the proliferat ion of human  umbilical vein endothel ial cells (HUVECS),  with 
particular  potency  against  VEGF -induced prolife ration.  The inhibition  of endothelial  proliferation a nd 
antiangioge nic activity  of Everolimus  was confirmed in vivo, as Everolimus  selectively  inhibited 
VEGF -dependent  angiogenic  response. Mice with primary  and metastatic  tumors  treated  with 
Everolimus  showed a significant  reduction  in blood vessel d ensity  when  compared to controls  at well 
tolerated doses. Additi onally,  activity  in a VEG F-impregnated  s.c. implant model  of angiogenesis  and 
reduced vascularity (vessel density)  of Everoli mus - treated  tumors  (muri ne melanom a) provided 
evidence of in vivo effects  of angiog enesis. 
 
Everolimus  also inhibits tumor  grow th in vivo in xenografted,  syngeneic,  and orthotopic  animal 
models,  residing longer  in tumor  tissue than in plasma  and demonstrating high tumor  penetration in a 
rat pancr eatic tumor  model.  These effects  occurred within  the dose range of 2.5 to 10 mg/kg  p.o. 
daily.  Typically, the antitumor  activity of Everol imus monot herapy  was that of reducing tumor  growth 
rates  rather  than producing regressio ns or stable disease.  
 
Everolimus,  administered p.o., was a potent  inhibitor  of tumor  growth and well tolerat ed in: 
 
• an s.c. mouse xenograft  model,  established from a variety  of tumor  cell lines of diverse 
histotypes  (NSCLC,  pancreatic,  colon,  melanoma,  epidermoid),  including a P-gp170 
overexpres sing multidrug -resistant  tumor  line 
• a series  of low-passage tumor  xenografts  established directly  from human tumor  material, 
maintained only in vivo and conside red highly  predictive  of therapeutic  outcome in patients. 
These included breast  (5 lines),  colorectal  (9 lines), gastric  (3 lines),  lung (22 lines,  including  
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  9 of 62  
 adenocarci nomas,  epidermoid cell, large cell and small  cell histotypes),  melanoma (6 lines), 
ovarian  (4 lines),  pancr eatic (3 lines), and renal  (6 lines).  
• in 2 syngeneic  models  (CA20948  rat pancreatic,  B16/Bl6 mo use orthotop ic melanoma) 
Taken  together, these d ata indicate the broad  antiproliferative potential  of Everolim us. 
It is not clear which  molecular  deter minants  predict  respo nsiveness of tumor  cells to Everolim us. 
Molecular  analysis  has revealed that relative  sensitivity  to Everolimus  in vitro correlates  with the 
degree  of phosphorylation (activation)  of the AKT/PKB protein kinase and the S6 ribosomal  protein. 
PTEN  status  alone  may not be predictive  of Everolimus  relative  in vitro sensitivity;  however,  in some 
cases (i.e., GBM)  there is also a cor relation with PTEN  status.  
 
In preclinical  models,  the administration of Everolimus  is asso ciated with reduction of protein 
phosphorylation in target  proteins  downstream  of mTOR,  notably  phosphorylated  S6 (pS6)  and p4E- 
BP1,  and occasionally  with an increase in phos phorylation AKT (pAKT).  
 
 
3.2.1  Preclinical  Safe ty  
 
In safety  pharmacologic  studies,  Everolimus  was devoid  of relevant  effects  on vital functions, 
including  the cardiovascular, respi ratory,  and nervous  systems. Everol imus had no influence on QT 
interval  prolongation.  Furthermore,  Everolimus  showed no antigenic  potential.  Although Everolimus 
passes  the blood- brain  barrier,  there was no indication  of relevant  changes  in the behavior  of 
rodents,  even after single oral doses  up to 2000 mg/kg or after repeated administration of up to 40 
mg/kg/day.  Based  on these findin gs, the potential  of Everolimus  to affect  vital functi ons in patients is 
considered to be low. 
 
Everolimus  is consi dered to have  no genotoxicity  or carcinog enicity  potential.  All significant  adverse 
events  observed  in preclinical toxicology studies  with Everolimus  in mice,  rats, monkeys,  and 
minipigs  were  consistent with its anticipated pharmacologic  action  as an antiprolifera tive and 
immunosup pressant,  and were,  at least in part, reversible  after a 2- or 4-week  recovery  period,  with 
the exception of the changes  in male  reproductive organs,  most notably  testes. Ocular  effects 
(lenticular  disorders)  observed  in rats were not observed  in any other  species  and are considered t o 
be a species-specif ic disorder.  
 
 
3.3 Clinical  Experience  
 
3.3.1  Everolimus  Pharmacokinetics  
 
Everolimus  is rapidly  absorbed with a median  tmax of 1 to 2 hours.  The bioavailability  of the drug is 
believed to be 11% or greater.  The area under  the curve (AUC) 0-τ is dose -proportional  over the dose 
range between 5 mg and 70 mg in the weekly  regimen and 5 mg and 10 mg in the daily regi men. C max  
is dose- proportional  between 5 mg and 10 mg for both the weekly  and daily regimens.  At doses of  20 
mg/w eek and higher, the increase in Cm ax is less than dose -proportional.  The coefficient  of 
variation be tween patients  is approximately  50%.  
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  10 of 62  
 Trough  levels  (24 hours  postdose)  correlate well with AUC 0-τ at steady  state during  daily 
administration.  
 
In whole blood, at a daily dose  of 10 mg, about  20% of Everolimus  is confined in plasma, with 26% 
being  unbo und. The remaining 80% is sequester ed in blood  cells.  
 
Everolimus  is extensively  metabolized in the liver and eliminated in the bile. Major  metabolites  are 
inactive.  Elimination  half-life is approximately  30 hours.  The clearance of Everolim us is 
approximat ely halved in patients  with mild-moderate hepatic  impairment  (Child -Pugh Class  A or B), 
while  renal  impairment  has little or no impact  on the pharmacokinetics  of Everolimus.  
 
Age, weight,  and sex in the adult  population  do not affect  the pharmacokinetics  of Everolimus  to a 
clinically  relevant  extent. The clearance of Everolimus  is reduced in children.  Pharmacokinetic 
characteris tics are not notably  different  between Caucasian and Japane se subjects, whereas  in 
Black  patie nts, populati on pharmacokinetic  studies  have  shown  an average 20% higher clearanc e. 
 
A high- fat meal altered  the absorpti on of Everolimus,  with a 1.3-hour delay  in tmax, a 60% reduction in 
Cmax, and a 16% reduction  in AUC.  
 
Everolimus  is a substrate of cytochrome P450  3A4 isoenzyme (CYP3A4)  and a substrate  and 
moderate inhibitor  of the multidrug efflux  pump P- glycoprotein (P-gp, MDR1,  or ABCB1).  Hence,  its 
metabolism  is sensitive to drugs  that modify  these enzymes  (substrates, inducers,  or inhibitors  of 
these  enzymes). Competitive  inhibi tion could  occur when Everolimus  is combined with drugs  that 
are also CYP3A4  or P-gp substrates.  
 
 
 
3.3.2  Everolimus  Pharmaco dyna mic Studie s  
 
Phar macokinetic/phar macodynamic  modeling based  on inhibition of the biomarker  p70S6 kinase 1 
[S6K1]  in peripheral  blood mononuclear  cells (PBMC)  sugg ests that 5 mg to 10 mg daily should b e 
an adequate dose to produce a high degree of sustained target inhibiti on ([Study  C2101] / [Study  
2102]).(16)  Furthermor e, molecular  pharmacodynamic  (MPD)  studies,  using immun ohistochemis try 
(IHC)  in biopsied tumor  tissue,  assessed the degree of inhibition and its duration  for pS6, p4E-BP1, 
and pAKT  expression with the daily and weekly  dosing.  There was high inhibition  of the downstream 
markers  S6K1  and 4E-BP1 at 5mg/day, which  was complete at 10 mg/day,  and preliminary  results 
suggest  an increase in pAKT expression,  with maximal  effect at 10 mg daily ([Study  C2107]).(17)  
 
 
3.3.3  Clinical Experience  with Everolimus  
 
Since  1996,  Everolimus  has been in vestigated as a component  of multidrug  immun osuppression in 
solid organ  transplantation.  On July 8, 2003,  the European Union  approved the use of Everolimu s, 
under  the trade  name  Certica n®, as prophylaxis  of organ  rejection in adult patients  receiving an 
allogeneic  renal or cardiac  transpla nt. The most  frequent  adverse drug reactions  in this setting  are 
highly  specif ic to the transplant  contex t. However, certain  events  are gene ralizable,  most notably  
myelosuppression,  skin disorders,  and increas es in blood lipid levels.  
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  11 of 62  
 In March  2009,  the United States  Food and Drug  Administration  (FDA)  approved  Everolimus  for the 
treatment  of advanced renal  cell carcinoma (RCC)  in patients  with advanced RCC after treatment 
with sunitinib or sorafenib has failed.  
 
Everolimus  has been  in developme nt for patients  with cancer since 2002.  As of August  31, 2008, 
approximat ely 4000 patients  with various  malig nancies  have been  treated in Novartis -sponsored or 
non-Novart is-sponsored studies, and in 3 healt hy volunteer  clinical  stud ies. Overall,  Novartis 
sponsored a total of 28 studies  of Everolimus  administered either  as single agent  (n=13) or in 
combination with other  antitumor  agents  (n=15).  Ongoing or completed investigator -sponsored 
studies  also enrolled over 1000  patients globally.  
 
Eight  single -agent,  Novartis-sponsor ed trials have been  or are being conducted  in various  advanced 
malignanci es. Five Phase  I studies  evaluated several  escala ting doses  with either  weekly or daily 
administration (Studies  C2101/02,  C2106,  C2107,  C1101)  of Everolim us, with the objective  to identify 
an optimal  regimen and dosage based on safety, pharmacokinetics,  and knowledge of the drug’s 
molecular  effec ts on various  tumors.  The 10 mg/day  and 50 mg to 70 mg/week  dosages  were 
proposed for further  studies when using  Everolimus  as a single  agent  and as a target maximum 
dose  in combi nation stu dies. In addition,  2 Phase I studies, one conduc ted in prosta te cancer (Study 
C2106)  and the other  in Japanese p atients  with advanced cancers  (Study C1101),  evaluated the 
safety  and the molecular  changes  in tumor  associated with the administration of Everolimus.  
 
Two Phase II monotherapy  studies  were  design ed to evaluate the safety  and efficacy of a single 
dose of 10 mg administered daily,  including Study C2235 in advanced  NSCLC  (n=81)  and Study 
C2239  in advanced pancreatic  neuroendocrine  tumors  (n=160).  
 
A Phase  III, randomized,  double- blind,  placebo- controlled study  in patients  with metastatic  RCC who 
progressed on a VEGFR TK inhibitor  (TKI)  demonstrated that everolimus,  adminis tered daily at an 
oral dose of 10 mg, provides positive clinical  benefit.(18)  Median progression- free survival (PFS)  
was prolonged from 1.87 months  for patients  recei ving placebo to 4.01 months  for everolimus - 
treated  patients, assessed by central  independent  review  blinded  to clinical data (hazard ratio,  0.30;  
95% CI, 0.22– 0.40;  p<0·0001).  
 
Updated results  presen ted at the American Society  of Clinical  Oncology  2009 Genitourinary  Cancers 
Symposium  (19) demonstrated everolimus  as having even greater  superiority  to placebo in the 
primary  endpoint  of PFS.  Median  PFS was prolonged from 1.9 months  for patients  receiving  placebo 
to 4.9 months  for everolimus -treated patients,  assessed by central  independent  review  blinded to 
clinical data (hazard  ratio,  0.33;  95% CI, 0.25– 0.43;  p<0.001).  
 
Overall,  the most  frequent  adverse effects  suspected  to be re lated to Everolimus  have  been 
stomatitis, r ash, anemia,  fatigue,  asthenia,  diarrhea, anorexia,  nausea,  hypercholeste rolemia, 
mucosal  inflammation,  vomiting,  hypertriglycerid emia,  cough,  peripheral  edema,  dry skin, epistaxis, 
pruritus,  and dyspnea.  The most common  grade 3 or 4 adverse reacti ons suspected to be related to 
treatment  were  anemia,  infectio ns, hyperglycem ia, stomatitis, fatigue,  lymphopenia, 
hypercholesterolemia,  pneumonitis,  and elevated gamma -glutamyltransferase conc entrations.  
Noninfectio us low-grade (grade  1/2) pneumonitis  has led to the development  of treatment  guidelines 
for the disorder. The primary  dose- limiting  toxicity  (DLT)  has been severe (grade  3) stomatitis  and, 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  12 of 62  
 occasiona lly, fatigue,  hyperglycemia,  and neutr openia.  Further detailed  information regarding  
Everolimus  clinical development,  safety, and efficacy  is provided in the [Investigator’s  Brochure].  
 
 
 
The trial is looking at an active agent,  namely  gemcitabine  in combinati on with a novel  agent  with 
pre-clinical data suggesting that urothelial cancer represents  a rationale  target  for m-TOR inhibition. 
A trial at Memorial  Sloan  Kettering Cancer  Center  (MSKCC)  (protocol  08-123) of Everolimus  in 
patients  with metastatic  transitional  cell carcinoma  of the urothelium  that has progressed after first- 
line therapy  with a 2-mo nth progression free survival  endpoi nt is ongoing.  
 
  
At MSKCC,  we perform ed an immu nohistochemical  (IHC)  study  to assess whether  mTOR pathw ay 
markers  are expressed in high-stage bladder  urothelial  carcin omas.  The study  was carried  out on a 
tissue microarray  of 92 cases of invasive urothelial  carcino ma of the bladder (≥ pT2) using 
antibodies  against  phospho- S6 and phospho- 4E BP1,  both markers  for an activated mTOR 
pathway.  Staining was graded  as 0 to 3+ (0=0-5%; 1+=6 -25%;  2+=26 -50%;  and 3+=>50%  tumor 
cells positive)  for phsop ho-S6 (cytoplasmic) and phospho-4E BP1 (cyto plasmic  and/or nuclear). 
Presence of at least two evaluable cores  from each tumor  was required f or inclusion  in the final 
evaluation.  The results  of immunor eactivity  in tumor  cells demonstrated that mT OR  pathway 
markers  are overexpressed in invasive  urothelial  carcinoma  of the bladder with correlation of 
expression seen  within  molecules  of the mTOR  pathway  using  Spearm ans correlati on coefficient 
(rho=0.411)  (see table below).(34)  This suggests that m-TOR targeted  therapies  may have activity in  
patients  with urothelial  carcinoma.  
 
Tumor  cell immunoreactivity  
Antibody  (# ca ses)  Grade 0 (%)  Grade 1+ (%)  Grade 2+ (%)  Grade 3+ (%)  
p-S6 (85)  45 (53)  11 (13)  9 (11)  20 (23)  
p-4E B P1 (8 4) 25 (30)  10 (12)  17 (20)  32 (38)  
 
3.4 Gemcitabine  
 
Gemcitabine (2',2'-difluoro-2' deoxycytidine;  Gemzar,  Eli Lilly and Co, Indianapolis,  IN) is a novel 
deoxy cytidine  analog  with a broad  spectrum  of antitumor  activity.  Gemcit abine has a molecular 
weight  of 299.66,  and after intracell ular activatio n, the active  metabolite is incorporat ed into DNA, 
resulting in inhibition of further  DNA synthesis. Gemcitabine may also inhibit  ribonucleotide 
reductase a nd cytidine deaminase as part of its cyto toxic activity.(20) Si nce its approval in 1996 by 
the FDA for the treatment  of pancr eatic cancer, (20-21) gemcitabine has been found  to have effective 
antitumor  activity  against  a broad  spectrum  of tumor  types, including  breast,  ovarian,  non-small  cell 
lung,  and bladder.  Studies  in patients with metastatic  transitional  cell carcinoma (TCC)  of the 
bladder  have  reported overall  response rates  to single-agent  gemcitabi ne that ranged from 22.5%  in 
previously  treated  patie nts to 28% in those who were  not previously  treated.(22- 24) These studies 
also report ed that single-agent  gemcitabine therapy was well tolerated and that the incidence of 
systemic side effects  was low. A multicenter,  randomized,  Phase III study  in patients  with 
Amended:  1/ 11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  13 of 62  
 unresectable and metastatic  bladder  cancer demonstrated th at a regimen consis ting of gemcitabi ne 
plus cisplatin had a better tolerabili ty and toxicity  profile  than the stand ard regimen of methotrexate, 
vinblastine,  doxorubicin,  and cisplatin (MVAC),  although overall  survival was similar  in both treatment  
groups.(25)  On the basis  of its excell ent clinical activity, patient  tolerability,  and chemical 
characteris tics, gemcit abine repres ents a logical  candidate for intravesic al therapy.  
 
3.4.1  Preclinical  Studie s  with Intravesical  Gemcitabine  
 
We studied  the toxicolo gy and pharmacokinetics  of gemcitabine delivered  intravesically  in dogs  to 
provide  the basis  for subsequent  clinical  studies. 
 
Methods:  Toxicolo gy (n=6): The animals  (in groups  of 2) received 100 mg, 350 mg, or 1 g of 
gemcitabine intravesically  on alternate days 3 times/week  for 4 weeks.  The animals  were  observed 
for signs  of toxicity;  gemcitabine levels and peripheral  blood  counts  were taken 3 times  weekly. 
Tetrahydrouridine (THU)  was added  to prevent  ex vivo degradation  of gemcitabine  by cytidine 
deaminase.  One dog from each group  was euthanized at day 1 after the last dose and the other  dog 
from each group  at day 14. Full necropsy was performed  in all animals.  Urine  specime ns with and 
without  THU were  examined to exclude any degradation of the drug.  Pharmacokinetics  (n=5): 
Intravesical  gemcitabine was given  at 100 mg (n=2),  350 mg (equivalent  to 1000mg/m2 human  
dose)  (n=2),  and 3.5 g (n=1).  Intravenous  gemcitabine was given at 350 mg (n=2).  Serum  samp les 
were  drawn at 30 minutes  and at 1, 2, 4, and 8 ho urs. 
 
Results:  Toxicology: 100 mg and 350 mg were well tolerated,  with no demonstrable side effec ts. At 
350 mg, the white  cell co unt nadir  was 2.9 and 3.1 (x103µl)  and the platelet  count  dropped to 97 and 
63 (x103/µl).  Necropsy revealed normal  bone marrow  cellularity,  normal  bladder  histology,  and no 
other  abnormalities.  At 1000  mg, signs  of severe  toxicity  were  seen;  these dogs received  only 3 
doses.  One dog died at day 3 following  cessation of treatment  and 1 was euthaniz ed at day 5 due to 
febrile neutropenia.  The necropsy  was consistent with hemorrhagic  cystitis and gastr ointestinal 
toxicity.  Pharmacokinet ics: At 100 mg and 350 mg, significant  systemic absorption of gemcitabine 
was seen,  with peak  serum levels  observed  at 1 hour and with detectable levels  up to 8 hours 
following  intravesical  gemcitabine.  For a given dose, the AUC for intravesical administration is 
approximat ely half that of the intravenous  infusi on. As the AUC is a better  predictor  of toxicity,  it is 
concluded t hat the equivalent  systemic dose,  if given  intravesically,  would be half as toxic.  
 
 
3.4.2  Clinical Experience  with Intravesical  Ge mcitabine  
 
We conduc ted a Phase I study  of gemcitabine a dministered intravesically  in 18 patients  with TCC of 
the bladder  refractory  to Bacille  Calm ette-Guér in (BCG),  and the results  showed excellent  tolerability 
to intravesical  gemcitabine given  twice  a week. (26) The patients  included 14 men and 4 women (4:1 
male/female ratio),  with a median  age of 74 years  (range,  37–86 years).  Stages  of bladder  cancer 
included refractory  0is in 12 patients  and recurr ent T1 carcin oma with or without  0is in 6 patients. 
Patients  were previously  treated  with 1 to 4 courses of BCG,  and 5 patien ts had been  previously  
treated  wi th  intravesical  chemotherapy,  including  mitomycin, valrubicin,  thiotepa,  and Adriamycin.  
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  14 of 62  
 Four intravesical do se levels of gemcitabine were evaluated:  500 mg, 1000 mg, 1500  mg, and 2000 
mg. Of the 18 eligible  patients, 3 were enrolled  at dose level I (500 mg), 6 at dose  level II (1000  mg), 
3 at dose level III (1500  mg), and 6 at dose level IV (2000  mg). Intravesical  gemcit abine was 
administered twice  weekly  in 2 courses of 3 weeks each,  with 1 week  of rest between courses, f or a 
total of 12 in stillations. At the end of 8 weeks, pa tients  were  evaluated for response.  Patients  who 
demonstrated CR (negative posttreatment  cytology  and cystoscopy)  underwent  close surveillance 
with serial  cystoscopies at 3-month intervals.  If recurrence was detected,  2 additional  courses  (3 
weeks  each,  separated by 1 week)  of intravesical  gemcitabine could  be considered,  followed by re- 
evaluation.  For patients  who did not achieve initial  CR or who suffered a relapse,  a radical 
cystectomy was recommended.  
 
Toxicity:  Gemcitabine as an intravesical agent was well tolerated.  The most commonly  observed 
toxicities  were as follows:  At dose level I (500 mg; n=3),  1 patient  had grade  1 nausea, and there was  
no urothelial  toxici ty. At dose  level II (1000  mg; n=6),  4 patients  experienced grade 2 urinary 
frequency  (more  than 2 times  normal  frequency  or urinatio n) and 1 experienced grade 3 urinary  
frequency  (more  than hourly  urination with urgency);  intermittent  gross  hematuria without  clots was 
present  in 3 patients,  2 patients  experienced grade 1 nausea  and fatigue,  and 1 patie nt had a skin 
reaction that resembled a grade  3 hand- foot syndrome.  At dose level III (1500 mg; n=3),  minimal 
urinary  symptoms  were  experienced by all 3 patients, but no systemic symptoms  were  observed.  At 
dose  level IV (2000  mg; n=6),  urinary  symptoms  were  minimal;  grade 3 t hrombocyt openia  and 
neutropenia was seen in 1 patient,  without  infectious  complications,  but no grade  4 systemic 
toxicities  were observed.  DLT was not reached;  2000 mg was the highest  soluble  dose in 100 mL of 
sodium  chloride. 
 
Phar macokinetics:  Levels  of gemcit abine in the serum  were  evaluated at all 4 dose le vels after the 
first, third,  seventh,  and ninth instillations. Serum  levels  of gemcitabine  were detected at dose level 
IV (2000  mg) in 2 patient s, including the patient  who experienced grade  3 thrombocyt openia  and 
neutropenia,  but were  undetectable at the first 3 dose levels  (500, 1000,  and 1500  mg). 
 
Based  on the results  of our Phase  I study,  we subsequently  conducted  a Phase II trial in patien ts 
with superficial  TCC of the bladder  who were refractory  or intolerant  to BCG  therapy  and who had 
refused  cystectomy.(27)  The patients  included  22 men and 8 women  (7:3 male/female ratio),  with a 
median  age of 70 years  (range,  43–89 years).  Stages  of bladder cancer  immediately  before 
intravesical  instilla tion included 0is in 23 patients,  T1 in 3 patients,  and incompletely  resected high- 
grade Ta in patients.  Of 30 patients,  27 were  refractory  to BCG and 3 were  intolerant  to BCG.  
 
Intravesical  gemcitabine at a dose of 2000 mg was adminis tered twice  weekly  in 2 co urses  of 3 
weeks  each,  with 1 week  of rest between courses, for a total of 12 instillations.  At the end of 8 
weeks, patients were  evaluated for response.  Patients  who demonstrated CR (cytolo gy and 
cystoscopy) underwent  close  surveillance with urine cytology  and serial  cystoscopies at 3- to 4- 
month intervals. For patients  who did not achieve initial CR, a radical  cystectomy was recommen ded. 
The median follow -up for all patients was 19 months  (range,  0 to 35 months).  Of the  
30 pa tients  treated with intravesical  gemcitabine,  15 (50%;  95% CI, 32%–68%)  had CR; however, 
only 21% (95%  CI, 0%–43%)  of these patients  were  free of recurrence  at 1 year.  Therefore,  of the 
total 30 patients  treated with intravesical  gemcit abine,  only 10% (95%  CI, 0%–21%)  were  free of 
recurrence  at 1 year.  Of the  15 patients who achieved CR, 14 were  available  for recur rence and 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  15 of 62  
 progression analysis:  12 had tumor  recurrence,  with a median  recurre nce-free survival time of 3.6 
months  (95%  CI, 2.9–11.0 months),  and 2 had no tumor  recurrence at 23 and 29 months, 
respectively. Overall,  2 patients  had progression to a higher  stage  while  receiving ge mcitabine 
therapy.  The median follow -up for patients  without progression or cystectomy was 19 months 
(range,  2 to 35 months).  Of the 30 patients,  11 (37%) underwent  a cystectomy after treatment  with 
gemcitabine;  4 of these 11 patients  had CR to the gemcitabine therapy.  
 
Toxicity:  Gemcitabine as an intravesical agent was well tolerated in this Phase II study, with a 
reported  toxicity  similar  to that of our Phase I study: grade  2 dysuria (occasional  pain or difficulty 
urinating)  in 3 patients,  grade 3 dysuria (continuo us difficulty  urinating ch aracterized by pain and 
frequency)  in 6 patients,  a rash on the glans  penis  in 1 patie nt, and cellulitis of the leg (requiring 
intravenous  antibiotics)  in 1 patient  who was on immunosu ppression therapy for a renal  transpl ant. 
 
The efficac y, safety,  and pharmacokinetics  of intravesical  gemcitabine have been evaluated in 2 
other  Phase I studies, albeit  using a less intensive weekly  schedule.  Laufer et al studied  the weekly 
administration of gemcitabine in 15 patients  who had recur rent TCC after intravesical  therapy.(28) 
Levels  of gemcitabine in the serum  were  low in patients  receiving 40 mg/mL,  and they were 
undetectable at concent rations  of 5 mg/mL,  10 mg/mL,  15 mg/mL,  and 20 mg/mL.  Levels  of the 
metabolite dFdU  (difluorodeoxyuridi ne), howev er, were  detectable in plasma  of patients  receivin g 
gemcitabine at concent rations  of 15 mg/mL  or higher,  which  implies  that the amount  of gemcitabine 
absorbed at lower  doses  is minimal.  Laufer  and colleagues  found that intravesical  gemcitabine  was 
well tolerat ed and had minimal  toxici ty, and 9 of the 13 patien ts available f or assessm ent were  free of  
recurrence  at 12 weeks. In their Phase  I study, De Berardinis  et al found that at concentrations  of 
40 mg/mL  gemcitabine was systemically  undet ectable,  but they were able to detect  the inactive 
metabolite dFdU  in plasma.(29)  
 
In our experience,  substantial  CR can be achieved initially  in patients  receiving intravesical 
gemcitabine,  but the 1-year durable CR was only 10% as the majority  of patients  underwent  a 
relapse  within  12 months,  which  supports the concept of combining intravesical  gemcitabine with 
other  agents  to improve  the durability  of CR. 
 
 
 
3.5 Carcinoma In  Situ (0is)  
 
3.5.1  Natural  History  of Bladder  Cancer  
 
More  than 70,000  new cases  of bladder cancer  are diagnos ed each  year in the United States.(30) 
Seventy  to 80% of bladder tumors  are non-muscle invasive tumors  (stage  Ta, Tis, T1), 25% are 
muscle invasive  (stage  T2, T3), and 5% are metastatic. Sixty to 70% of non-muscle invasive  tumors 
recur,  while  20% to 30% progress  to a higher  stage or grade.(31)  
 
Superficial  or non-muscle invasive urothelial  bladder cancer  (UBC)  includes  stages  Ta, T1, and Tis 
(carcinoma in situ – 0is), with frequencies  of 60%, 30%,  and 10%,  respectively.  The term “non- 
muscle invasive  bladder  cancer”  embraces  a spectrum  of tumors  with varying  degrees  of clinical 
behavior.  The low-grade Ta lesions  common ly recur but rarely  progress  to muscle invasion.  On the 
other  hand,  T1 tumors  represent  a heterogeneous  populati on, including some  of which  behave  in an 
indolent  fashion  and typically  respo nd to conserv ative therapy,  as well as others  that behave more 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  16 of 62  
 aggressively  and progress  to muscle invasion  and even metastatic  disease.  At present,  we lack the 
ability  to predict the clinical behavior  of T1 tumors  prospec tively.  
 
 
 
3.5.2  Recurrence 
 
Recurrence rate after transurethral  resection (T UR) ranges  from 30% to 90%,  depending on size, 
site, multifocality,  the presence  of 0is, grade,  and prior history  of bladder  cancer.  The high 
recurrence  rate and the unpredictability  of the progression p attern of bladder cancer  have  led to the 
widespread use of intravesical  therapy as a supp lement  to TUR.  Non-muscle invasive UBC lends 
itself to intrav esical  therapy owing to direct  contact of the chemotherapeutic  agent  with the bladder 
mucosa and tumor.  Furthermore,  some  agents  can be used  at high doses, with minimal  systemic 
side effec ts due to minimal  absorption.  
 
In a prospective longitudinal  study,  the National  Bladder  Cancer  Collaborative  Group  A (NBCCGA) 
identified a group  of patients  with superficial TCC treated  solely  by TUR and identifi ed the factors 
implicated  in tumor  recurrence.  In this study, size itself did not seem  to be a factor  unless  it was 
greater  than 5 cm. An increased  recurrence rate occurred  in patients  with multiple  tumors,  Grade  3 
disease,  concomitant  0is, lamina propr ia invasion,  and positive  cytology.(32)  
 
 
3.5.3  Progression  
 
Progression is defined as the development  of muscle invasion or metastasis and occu rs in 20% to 
30% of patients who present  with superficial d isease. The NBCCGA  identified tumor  grade,  lamina 
propria  invasion,  and associated 0 is as indicators of progression.  Two percent  of patients with grade 
1 tumors  progressed co mpared to 11% with Grade  2 and 45% with Grade  3, with the majority 
progressing within  24 months  of diagnosis.(32)  Four percent of patients  with Ta lesions progressed 
versus 30% with T1 tumors.  Eight  percent  of tumors without  mucosal  abnormalities  progressed 
versus 33% with moder ate to severe  dysplasia.  In a compilation  of data,  Herr et al reported a 29% 
progression for T1 tumors  and 40% for T1 G3. (33) It is clear  that the poor prognosis  of superfici al 
TCC is predominantly  due to patients with T1 disease.  The high recurre nce rate and t he 
unpredictability  of the progression p attern have led to the investigation of new approaches.  
 
 
3.5.4  Current Concepts  in Intravesical  Ther a py 
 
Superficial  bladder  cancer  lends  itself to intravesical  therapy  due to the direct  contact  between the 
chemotherapeutic  agent  and the tumor.  Furthermore,  very high doses  of some  agents  could  be used 
with minimal  systemic side effects  due to the lack of absorption (e.g.,  mitomycin  is given  at a dose of 
40 mg weekly  for 8 weeks). This led to the widespread use of intravesical  therapy  after resecting the 
papillary  tumors  endoscopical ly or documenting the prese nce of diffuse  0is. BCG,  thiotepa, mitomycin  
C, and doxorubicin have b een used  as intravesical agents.  The highest  tumor -free success  rate has 
been  reported  after intravesic al BCG  therapy. Multicenter  studies  have shown that thiotepa and 
doxorubicin are inferior  to BCG  in preventing  tumor  recurrences. In studies comparing mitomycin and 
BCG,  initial tumor -free response r ates are comparable for the 2 agents, with some studies  suggesting  
an advantage for BCG therapy. In a randomized trial comparing BCG to no Amended:  1/11/11 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  17 of 62  
 intravesical  therapy,  38% of patien ts treated  with BCG progressed at 10 years  versus 63% for the 
control  group. There was no significant  difference  between groups  with regard  to stage. Progression 
was defined as muscle invasion or metastatic  disease.  The median  survival times  for both groups 
have  not been  reached.  Ten-year survival in BCG was 75% compared  with 55% in the control  group. 
Patients  with an initial in complete response  to BCG have a poor outcome.  The overall  risk of 
progression is 95% at 5 years  for 0is patients  with an incomplete response but only 19% in those 
with an initial CR. Alternative  therapies  are needed for patien ts who fail B CG. Mitomycin  C, with a 
15% respo nse when  given intravesically,  is the most  active chemotherapeutic  agent. Despite this 
level of activity, mitomycin  C has neither delayed progression nor preserving the bladd er. Thus, 
more  active agents  need  to be identi fied. 
 
BCG  is associated with toxicity  in the form of local complicatio ns, such as cystitis  in 90% of patien ts, 
requiring interruption  of treatment  in 3.6%,  hematuria in 9%, epididymitis  in 0.4%,  contracted  bladder 
in 0.2%,  granulomatous  prostatitis  in 0.9%,  renal  abscess in 0.1 %, and ureteral  obstruction in 0.3%. 
Systemic complications  represent  the main  concern in BCG -treated  patients. Fever  up to 38.5°C  is 
frequently  observed,  pneumonia and hepatitis  have been reported in 0.9% of patients, and sepsis in 
0.4%.  
 
Everolimus  selectively inhibits  mTOR  (mammal ian target  of rapamycin),  a serine -threonine  kinase, 
which  is present  in all cells and a central regulat or of protein synthesis a nd ultimately  cell growth, 
proliferation,  angiogenesis  and survival.(1) mTOR  is downstr eam of PI3K (phosphatidyl -inosit ol-3- 
kinase)/AKT, a pathway  known to be dysregulated in a wide spectrum of human cancers  through 
various  potential  mech anisms  including loss/mut ation of the PTEN  (phosphatase and tensin  homolog 
deleted  on Chromosome 1 0) negative regulator,  PI3K mutation/amplificati on, AKT/PKB 
overexpres sion/overactivation,  and/or  modulation of TSC1/TSC2  tumor  suppressors. In addition, 
activation of the PI3K/AKT/mTOR  pathway  is frequently  associated with increased aggressiveness, 
resistance to treatment  and progression.  Previous  work has demonstrated the over-expression of 
activated mTOR  pathway  markers  including ph ospho- S6 and phospho -4E BP1 in invasive  urothelial 
carcinoma specimens.(34)  Preclinical studies  have  demonstrated that that mutational  activation  of 
the PI3K  pathway  through loss of PTEN or activation of the serine/threonine kinase,  AKT, makes 
tumor  cells more sensitive to the anti-tumor  effects  of mTOR  inhibitors.( 35-38) These findings  have 
provided the rationale to explore  the anti-tumor  activity of mTOR in hibitors  in patients with PTEN - 
deficient  tumors  with a proof -of-concept  phase  1 neoadjuvant  trial of rapamycin in patients  with 
recurrent  glioblastoma whose tumors  lacked  PTEN  expression demonstrating anticancer activity. 
(39) 
 
 
 
3.6 Rationale  for this  Study  
 
Rationale  for this study  includes  the following:  
 
1) Standard  manageme nt for patients  with high-risk superfici al disease who fail BCG therapy  is 
removal  of the bladder  (cystectomy). There  is a paucity  of active agents  for patients  who fail 
intravesical  BCG,  none  of which  eliminates  the need for cystectomy. 
 
  
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  18 of 62  
 2) Patients  wish to avoid  a cystecto my because cystectomy  generally  requires  an external  collecting 
device for urine,  which  is associa ted with poor self-image  and quality  of life. Surgery  results  in 
impotence in men due to the need to remove  the prostate as part of the surgical procedure.  
 
3) The favorable activity  of gemcitabine,  includin g CR, when given  systemically in metastatic 
urothelial  carcinoma  and transient  CR when  used intravesically  for non-muscle-invasive UBC.  
 
4) The acce ptable clinical toxicity  profile  of gemcitabine when given  intravesically.  
 
5) The need  to increase the durabili ty of the response to intravesical ch emotherapy.  
 
6) This proposed  study  targets  patients with stage 0is UBC who have  failed or have relapsed after 
intravesical  BCG,  the standard treatment  for this stage  of disease.  Unfortunately,  standard therapy  is 
frequently  ineffective in the setting  of persistent  or recurrent  disease. Persistent or recurrent  0is after 
BCG  is an ominous  sign. Despite the poor prognosis,  some  patients  refuse cystecto my because  of 
quality  of life concerns  and request  alternative  treatment.  The standard  of care for patients  who 
failed  or d id  not respond to BCG has not changed in over 25 years  and new approaches  are needed 
for this patient populati on. 
 
7) Intravesical  valrubicin  is the only agent approved  by the FDA.  It is a modestly  active  agent  in this 
setting, with a 21% CR rate reported in a Phase II study, and a 1-year durable CR of 13%.  It is 
infrequently  used in the urologic  communi ty because of the significant  local toxicity  and short 
durability  of the response.  
 
8) We have  shown that gemcitabine given  twice weekly  was associat ed with minimal  bladder  
irritation  and tolerable myelosuppression.  We proceeded with a Phase II study, documenting a CR of 
50%.  However,  the 1-ye ar durable CR was only 10%,  suggesting a need  for maintenance therapy. 
 
9) There is a clear  need for novel  agents  in BCG-refractory  0is. Furthermore,  an active  agent  that 
can be administered systemically has the added  advantage of potentially  treating  upper tract 
disease,  which  occurs  in 20% of this patient  population.  
 
10) The mTOR  inhibitor  Everolimus  has been  shown to inhibit  protein  synthesis and g rowth  of 
bladder  cancer  cells in vitro.  Everolimus  is efficacious  in treating bladder  cancer cells in vivo. mT OR 
inhibitors  have also shown synergism with gemcitabine in pancreatic  cell lines, supporting  the 
concept  of combination therapy  using  Everolim us with intravesical  gemcitabine.  
 
  
4.0OVER VIEW  OF STUDY DESIGN/INTERVENTION  
 
4.1Design  
 
Patient  population  
 
Sample size: In Phase  I, a minimum of 2 and a maxim um of 18 patients  will be accr ued. In Phase II, a 
minimum of 33 and a maximum of 45 patients  will be accru ed (6 can be carried over from the MTD 
cohort  of Phase I). 
 
Time  required for accrual of all patients: 24 months  (estim ate) 
Average accrual  rate per month : 1-2 patients  
Sites:  Single  institution (MSKCC)  
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  19 of 62  
 Recruitment  plan:  All MSKCC  patients with stage TisN0M0  TCC of the bladder  who have failed  or 
relapsed after intravesical  BCG will be offered  the protocol.  Both sexes  and all racial and ethnic 
groups  will be eligible  to participate  in this clinical trial, provi ded all the other eligib ility criteria  are 
met. The surgeons  will meet  weekly  with the involved medical  oncologists to discuss study  patients.  
 
 
Phase  I: 3 dose levels  of continuous  Everolimus  (Everolimus  dose levels:  Dose  level 1: 5 mg every 
other  day, Dose  level 2: 5 mg daily,  and Dose  level 3: 10 mg daily)  in combination with a fixed dose 
of intravesical  gemcitabine at a dose  of 2000  mg twice weekly  for 3 weeks, followed by a week  of 
rest from gemcitabine —this  is the first 28-day cycle—and  a second course of intravesical 
gemcitabine,  also followed by a week of rest from gemcitabine —the  second  28-day cycle—will b e 
evaluated using  the DLT rules  outlined below:  
 
Table  4.1-1  
Number of subjects  with DLT Action 
 
0 of 3 subj ects Esca late to next highest dose level and enroll  up to 
3 sub jects 
1 of 3 subj ects Enroll up to 3  more subj ects at the sa me dose level  
 
1 of 6 subj ects Esca late to next highest dose level and enroll  up to 
3 more  subjects 
2 or 3  subjects in the first 3 
subjects De-escalate to low er dose level and e nroll up to 6 
subjects 
 
≥ 2 of 6 subje cts De-escalate to low er dose level and e nroll up to 6  
subjects 
 
If 2 of the first 2 subjects have DLT, the enrollment  of a third subject at the same  dose  level is not 
necessary.  Similarly,  if 2 of 4 subjects or 2 of 5 subjects  have DLT, it is not necessa ry to enroll 
subsequent  subjects at the same  dose level.  All the Everolimus  doses  will be given  in addition t o 
intravesical  Gemcitabine at the dose of 2,000mg in 100cc  twice weekly.  
 
There will be no plann ed dose  level below  dose level 1. If ≥ 2 DLTs  occur  at dose level 1, then the 
study  will be terminated.  
 
There will be no plann ed dose  level beyond  dose  level 3. If no DLTs  occur at dose l evel 3, the 
Phase  II portion  of the trial will be init iated.  
 
The MTD  is the dose level at which  no more  than 1 out of 6 patients  experience DLT. 
If ≥ 2 subjects at the first dose level experience DLT, then the study  will be terminated  and the 
combination of Everolimus  at a dose of 5 mg every other  day with intravesical  gemcit abine at a dose 
of 2000  mg twice  weekly  will be considered unsafe in this population.  
 
Patients  will be observed for DLTs  through the 3rd cycle  of treatment  (the first three  28-day cycles) 
prior to dose  escalation f or the next dose level for the next cohort  of patients. No intrapatient  dose 
escalation will occur. DLTs  will be de fined as follows, using  NCI Common Terminology  Criteria  for 
Adverse Events  (CTCAE)  version 4.0: 
 
1)  Any evidence of grade  3 or 4 toxicity  under  Renal  and Urinary  Disorders  in CTCAE  version 4.0. 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  20 of 62  
 2)  Febrile neutropenia (absolute  neutr ophil count  (ANC)) < 1000/ μL plus oral temperature to 
38.5°C)  
 
3)  Grade  4 neutropenia (ANC  <500 /μL) for ≥ 7 days 
 
4)  Other  grade  4 hematologic  toxicity  
 
5)  Other  nonhematologic  grade  3 or 4 treatment -related toxicity,  excluding n ausea/vomiting,  rash, 
untreated hyperlipidemia or grade  3 fatigue lasting ≤ 7 days. 
 
6)  Any nonhe matologic  toxicity  requiring  treatment  delay  for > 7 days during cycle 1. 
 
Phase  II: Patients  will receive continuous  Everolimus  administered at the dose  deter mined  from the 
Phase  I part of the study  and intravesical  gemci tabine at a dose of 2000  mg twice  weekly for 3 
weeks  followed by a we ek of rest from gemcitabine—this  is the first 28-day cycle—a nd a second 
course of intravesical ge mcitabine  followed  by a week of rest from gemcitabine —this  is the second 
28-day cycle. Everolim us will be con tinued for 12 months  in the patients  who achieve a CR. Patients 
demonstrating a CR (by cystoscopy and cytology)  will be observed with serial  cystoscopies every 3 
months.  
 
4.1.2  Proposed  Correl ative Studies  
 
1) Analysis  of pretreatment  tumor  tissue specimens in all patients by immu nohistoche mistry  markers 
of activated mTOR  pathway  phsopho- S6 and phospho- 4E BP1 as well as PTEN,  .phospho -AKT and 
PRAS 40, a downstream  substrate of AKT.  The total number  of unstained slides  required for this is 
10 unstained slides  or 1 paraffin -embedded block. This will not require  research biopsies. 
 
 
The staining will be performed  at the Core  Lab of MSKCC’s  Department  of Patholo gy. The stains  will 
be evaluated by the GU pathologist  on this protocol (Hikmat  Al-Ahmadie)  and the staining will be 
graded  as 0 to 3+ (0 = 0-5%; 1+ = 6-25%;  and 3+ = >50%  tumor  cells positive).  
 
2) Pretreatm ent tumor  samples  will be evaluated for PTEN  and PIK3CA mutational  status using 
bidirection al full length  sequencing.  This assay  will be performed  by either Sanger  sequencing 
and/or  the Sequenom  technique at the DNA Sequencing Core Facility  at MSKCC.  This assay will 
require  2 cu rls of 10 microns  of the formalin- fixed paraffin- embedded tumor  tissue sections. 
 
 
4.2Intervention  
 
Everolimus  administration  
 
The study  drug Everolimus  will be se lf-administer ed on an outpatient  basis. The investigator  will 
instruct the patient  to take the study  drug exactly  as specified in the protocol.  Patients will be 
required to maintain  a pill diary (Appendix  1, Appendix  2, and Appendix  3). Everolim us will start o n 
Cycle  1, Day 1 of intravesical  therapy and will be taken  continuously.  
 
Phase  I: Everolimus  will be adminis tered as follows: 
Dose  level 1: 5 mg every  other  day 
Dose  level 2: 5 mg daily 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  21 of 62  
 Dose  level 3: 10 mg daily 
 
Phase  II: Everolimus  will be adminis tered at the dose determined in Phase  I. 
Gemcitabine administration  
• Patients  will receive  a dose  of 2000  mg of intravesical  gemc itabine twice  a week  (72–96 hours  
between doses) for 3 weeks for a total of 6 treatments  in course 1. After 1 week  of rest from 
intravesical  gemcitabine,  course  2 will be admi nistered,  provided  the treating physician notes 
acceptable patient  tolerance.  The total number  of intravesical  instillations  will be 12. 
• All intraves ical chemot herapy  will be administered to the patient in the Urology  Clinic  on an 
outpatient  basis and kept in the bladder for 1 hour.  
 
 
 
5.0THERAPEU TIC/DIAGNOSTIC  AG ENT S  
 
5.1 Everolimus  
Everolimus  is a novel  oral derivative  of rapamycin.  Everolim us will be ad ministered  orally  
continuously  from study  day 1 until progression of disease or unacceptable toxicity.  Patients  will b e 
instructed to take Everolimus  in the morning,  at the same  time each day. 
 
Everolimus  should  be taken by the patient  in a fasting state  or with no more  than a light fat-free 
meal.  Dietary  habits  around the time of Everolimus  intake  should be as consistent as possible 
throughout  the study. 
 
If vomiting  occurs, no attempt  should be made  to replace  the vomited dose.  
 
5.1.1  Drug  Dispensing/Administration  
 
Administration will be pe rformed  on an outpatient basis. Everolimus  will be dispensed as tablets  at 
the beginni ng of each treatment  cycle. In case of dose  modif ication,  patients will be asked to return 
all of their previously  dispensed medication to the clinic and they will be dispensed new- strength 
tablets.  
 
All dosages  prescribed  and dispens ed to the patient  and all dose changes during the study  must be 
recorded.  
 
Medication l abels  will co mply with US legal  requirements  and will be printed in English.  They  will 
supply  no information about  the patient. The storage conditi ons for study  drug will be described o n 
the medication  label.  
 
Everolimus  will be provided by Novar tis. Everolimus  is formulated  as tablets for oral administrat ion of 
5mg strength.  Tablets  are blister -packed under  aluminum  foil in units of 10 tablets, w hich should  be 
opened  only at the time of administration as drug is both hygroscopic  and light-sensitive.  
 
 
Amended:  1/11/11  
Page  22 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 5.1.2  Storage  and Stability  
 
 
Current  stability  data permit a shelf life of either  36 months  (for 5mg tablet  variants  based  on solid 
dispersion d ried by evaporation/drying oven)  or 24 months  (for 2.5mg,  5 mg and 10 mg tablet 
variants  based  on solid dispersion d ried by paddle dryer),  assuming correct storage  below  30°C  in 
the original  double -sided aluminium  blister  packaging and pr otected from light and moisture.  
 
5.1.3  Source  of Drug  
Novartis, Inc. will supply  Everolimus  free of charge. 
 
 
5.1.4  Drug  Accountability  
All study  drug supplies  must be kept in a locked room  with limited  access. The study  drug must not be  
used  outside the context of this protocol.  Under no circumstances  should the investigator  or other site 
personn el supply  study drug to other  investi gators,  patients, or clinic,  or allow  supplies to be 
used  other  than directed by this protocol  without  prior authorization from Novartis. 
 
 
The pharmacist  will maintain a complete drug a ccountability  record for each tablet  strength with lot 
numbers  of each drug r eceived,  including  the number  of bottles  dispe nsed to each pa tient, the dates 
drug was dispensed,  and the daily dose  of Everolimus  the patient  recei ved. The prescribed  dose 
should  also be recorded in the patient’s medical  records.  
 
At the conclusion  of the study, all un used Everolimus  tablets  will be returned to Novartis for 
destruction.  
 
5.1.5  Toxic ity 
Adverse events most frequently  observed with Everolimus  are rash,  stomatitis/oral  mucositis, 
fatigue,  headache,  anorexia, nausea,  vomiting,  and diarrh ea. Infections  have  not been  notably 
frequent  or severe.  Non-infectious  pneumonitis  has also been observed.  The majority  of these AEs 
have  been  of mild to moderate  severity  (CTC  grade 1- 2). Overall, the most frequently  observed 
laboratory  abnormalities  include  reduced  blood  counts,  hyperglycemia and hyperlipidemia  mostly 
reported  as hypercholesterolemia and/or  hypertriglyceridemia.  
 
Other  less common  adverse events  include  respiratory,  thoracic  and mediastinal  disorders  such as 
dyspnea,  pleural  effusi ons, cough,  hemoptysis and acute respiratory  failure;  general  disorders  such 
as fever,  general  health  deterioration, creatinine increase,  hypercalcemia and chest p ain; 
musculoskeletal  and connective tissue disorders  such as back pain,  pathologic  fractures and bone 
pain;  and psychiatric disorders  such as confusio nal state.  
 
5.2 Ge mcitabine  (GEM ZAR®)  
 
 
5.2.1  Investigational  Drug  Description  
Gemcitabine is a pyrimidine  analo gue of deoxycytidine in which  the deoxyribose  moiety contains  2 
fluorine  atom s at the 2’position.  The drug acts as an inhibitor to ribonucleotide reductase and 
 
Amended:  1/11/11  
Page  23 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 inhibition  of DNA synthe sis may result  in pertur bations  of deoxynucleotide  pools  and interference 
with DNA chain elongation.  The drug is cell-cycle specific  and blocks cells in the G1/S interface. 
Cytot oxicity  is sched ule dependent  and increas es with increasing durati on of exposure.  The drug is 
rapidly  eliminated  from plasma,  owing mainly  to deamination.  Renal  clearance of drug is less than 
10% of parent  drug.  
 
 
5.2.2  Availability  
The drug is supplied as either  a 200 mg or 1 gram  lyophilized  powder  in a 50mL  sterile  single  vial for 
reconstitutio n. 
 
5.2.3  Administration  
The drug is administered via a freely  running  intravenous  catheter  per institution al guidelines.  
 
 
5.2.4  Toxic ity 
Toxicities  include naus ea, vomiting,  alopecia,  stomatitis,  anorexia,  fatigue,  elevations  of hepatic 
transaminases,  rash,  flu-like symptoms, edema,  constipa tion, paresthesias,  hypersensitivity 
reactions,  phlebitis,  proteinuria,  hematuria,  reversible myelosuppression,  rarely  interstitial 
pneumonitis  and ARDS  and rarely  kidney  dama ge. 
 
 
6.0CRITERIA  FOR  SUBJECT  ELIGIBILITY  
 
6.1Subject  Inclusion  Criteria  
 
• Patients  must have  BCG refractory  TisN0M0.  BCG -refractory  disease is defined  as: 
• Patient  positive for Cis after 2 consecutive BCG  installatio ns 
• OR, patient  had a BCG response and failure  within 6 months  
• OR, Cis on maintenance BCG 
• Pathologic  confirmation  of urothelial  carcinoma by the Depar tment of Pathology  at MSKCC  
• Karnofsky  Performance Status  (KPS)  >70% 
• Age ≥ 18 years 
• Adequate bone  marrow  function  as shown  by: 
• ANC ≥ 1.5 x 109/L 
• Platelets  ≥ 100 x 109/L 
• Hb >9 g/dL 
• Adequate liver function as shown by: 
• serum  bilirubin ≤ 1.5 x UL N (upper  limit of normal)  
• ALT and AST ≤ 2.5x ULN 
• International  normalized ratio (INR)  ≤1.5 x ULN.  (Anticoagulat ion is allowed if target  INR ≤ 1.5 x 
UL N on a stable  dose of warfarin  or on a stable dose of low molecular  weight  (LMW) heparin for 
>2 weeks) 
 
• Adequate renal  function:  serum  creatinine ≤ 1.5 x ULN 
Amended:  1/11/11  
Page  24 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 • Fasting  serum cholesterol  ≤300 mg/dL OR ≤7.75 mmol/L  AND fasting  triglycerides  ≤ 2.5 x ULN.  
NOTE:  In case one or both of these t hresholds  are exceeded,  the patient  can only be included 
after initiation of appropriate  lipid-lowering medication.  After lipid-lowering therapy,  patients  must 
meet  the same  criteria,  i.e. a fasting  serum  cholesterol  < 300 mg/dL  OR < 7.75 mmol /L AND 
fasting  triglycerides  < 2.5 x ULN,  to be eligible  for study  treatment.  
• Pre-treatm ent tumor  tissue (minim um 10 sli des) or 1 paraffin- embedded  block  available  for 
analysis  of m-TOR pathway  markers.  
• Testing  for hepatitis  B vir al load and serologic al markers  (HBV -DNA,  HBsAg,  HBsAb,  and 
HBcAb)  for the following patients:  
 
• All patients  who currently  live in (or have  lived in) Asia,  Africa,  Central  and South  America, 
Eastern Europe,  Spain,  Portugal,  or Greece 
 
• Patients  with any of the following  risk factors:  
 
• Known or suspected past hepatitis  B infection  
 
• Blood trans fusion(s)  prior to 1990  
 
• Current  or prior IV drug users  
 
• Current  or prior dialysis  
• Household contact  with hepatitis  B infected person(s)  
• Current  or prior high-risk sexual  activity  
• Body  piercing or tattoos  
• Mother  known  to have hepatitis  B 
• History  suggestive of hepatitis  B infection,  e.g. dark urine,  jaundice,  or right upper  quadrant 
pain 
• Additional  patients  at the discretion of the investigator  
• Testing  for hepatitis  C infection  (using quantitative RNA-PCR)  for patients  with any of the 
following  risk factors: 
• Known or suspected past hepatitis  C infection  (including patients with past interferon 
“curative” treatment)  
• Blood trans fusion(s)  prior to 1990  
• Current  or prior IV drug users  
• Household contact  of hepatitis  C infected person (s) 
• Current  or prior high-risk sexual  activity  
• Body  piercing or tattoos  
• Additional  patients  at the discretion of the investigator  
 
 
6.2Subject  Exclusion  Criteria  
 
 
 
 
 
Amended:  1/11/11  
Page  25 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 • Patients  currently  receiving antica ncer therapi es or who have received anticancer  therapies 
within  4 weeks  of the start of study  drug (includi ng chemotherapy,  radiation therapy,  antibody 
based therapy, etc.) 
• Patients,  who have had a major  surgery  or significant  traumatic  injury  within 4 weeks  of start of 
study  drug,  patients  who have not recovered from the side effects  of any major  surgery  (defined 
as requiring general  anesthesia) or patients  that may require major  surgery  during  the course of 
the study  
• Prior  treatment  with any investigati onal drug within the preceding 4 weeks  
 
• Patients  receiving chronic,  systemic treatment  with corticoste roids  or another 
immunosuppressive ag ent. Topical  or inhaled  corticosteroi ds are allow ed. 
• Patients  should not receive  immunization with attenuated live vaccines within  1 week  of study 
entry  or during  study  period 
• Other  malignancies  within the past 3 years, except  for adeq uately treated  carcinoma of the 
cervix, basal  or squamous  cell carcin omas  of the skin, or adenocarcinoma of the prostate that 
has been surgically  treated with a post-treatment  PSA that is non-detectable.  
• Patients  who have  any severe and/or  uncontrolled medical  conditions  or other  conditions  that 
could  affect  their partici pation in the study  such as: 
• sympto matic  conges tive heart  failure  of New York Heart  Association Class III or IV 
 
• unstable an gina pectoris,  symptomatic  cong estive heart  failure,  myocardial  infarc tion 
within  6 months  of start of study  drug,  serious  uncontrolled cardiac  arrhythmia,  or any 
other  clinically  significant  cardiac  disease 
• Severely  impaired lung function as defined by spirometry  and diffusing ca pacity  of lung for 
carbon  monoxide (DLCO)  that is 50% of the normal  predicted value  and/or  02 satura tion that is 
88% or less at rest on ro om air 
 
• Uncontroll ed diabetes  as defined  by fasting  serum glucose >1.5 x UL N 
 
• Active (acute  or chronic)  or uncontrolled severe infections,  including urinary tract infections  
 
• Liver  disease such as cirrhosis, chronic active  hepatitis,  or chronic  persis tent hepatitis  
 
• A known history  of HIV seropositivity  
 
• Impairment  of gastroint estinal  function or gastroi ntestinal  disease that may significantly  alter the 
absorption of Everolimus  (e.g.,  ulcer ative disease,  uncontroll ed nausea,  vomiting,  diarrhea, 
malabsorption syndrome,  or small -bowel  resection)  
• Patients  with an active, bleeding diathesis  
 
• Female  patients  who are pregnant  or breast  feeding.  Women of childbearing  potential must  have 
a negative serum  pregnancy  test within  7 days prior to administration of Everolimus.  
• Adults  of reproductive  potential  who are not using effective  birth control  methods.  If barrier 
contracepti ves are being  used,  these must  be continued throughout  the trial by both sexes. 
Hormonal  contraceptives  are not acceptable as a sole method  of contr aception.  Patients  who 
have  received  prior treatment  with an mTOR  inhibitor  (sirolimus,  temsirolimus,  Everolimus)  
 
 
Amended:  1/11/11  
Page  26 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 • Patients  with a known hypersensitivity  to Everol imus or other  rapamycins (sirolimus, 
temsirolimus)  or to its excipients  
• History  of noncompliance to medical  regimens  
 
• Patients  unwilling  to or unable to comply with the protocol  
 
• Prior  radiation  to the pelvis  
 
 
 
7.0RECRUI TM ENT  PLAN  
 
Patients  will be recruited from the outpatient  clinics of the Urology and Genitourinary  Oncology 
Services at Memorial  Sloan-Kettering Cancer  Center  (MSKCC).  Potential  research subjects  will be 
identified by a member  of the patien t’s treatment  team,  the protocol  investigator,  or the research 
team.  If the investigator  is a member  of the treatment  team,  s/he will scr een their patient’s  medical 
records  for suitable research study  participants  and discuss the study  and their poten tial for enrolling 
in the resea rch study. Potential  subjects  contacted by their treating  physici an will be re ferred  to the 
investigator /research sta ff of the study. The patient’s  initial conversation with the investigator /research  
staff and portions of the patient’s  MSKCC  medical  records  will be used to confirm  that the patient  is 
eligib le for study  participation.  
 
8.0PRETRE AT M ENT  EVALU AT IO N  
 
Within  7 days of start ing treatment:  
 
• Pre gnan cy test: Adequate contrac eption  must be used while  on study  and for 8 weeks  after 
last dose of study  drug 
 
Within  14 days of starting  treatment:  
 
• Hematology  
 
o Complete Bl ood Count  including:  hemoglobin,  hematocrit,  platelets,  total white  blood 
cell count (WBC)  and differential.  
o PT (INR)  evaluation  will be included for baseline evaluations.  
 
• Blood che mistry  
 
o Comprehen sive Metabolic  Panel  including:  sodium, potassi um, chloride,  bicarbonate, 
calcium,  glucose, creatinine,  blood urea nitrog en, albumin,  total protein,  SGOT  (AST ), 
SGPT  (ALT),  total bilirubin, alkaline  phosphatase,  
o Uric acid, 
o Phosphorus,  
o Serum  lipid profile  (triglycerides,  total choles terol, HDL,  and LDL).  
o Because  accurate  serum  glucose  and lipid me asure ments  are required, 
patients should  be fasting  at the time of the blood  sampling.  
 
 
 
Amended:  1/11/11  
Page  27 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 • Urina lysis 
 
o Standard urinalysis.  This must be supplemented with laborat ory quantification of any 
potentially  relevant  abnormalities.  
 
• Vital  signs  
 
o Vital sign assessment consists of height (first visit), pulse, blood pressur e, respirati on 
rate, temperature,  and weight.  Blood  pressure,  pulse, and respiration  rate should be 
measured on patients  after at least 3 minutes  in the sitting  position.  
 
• History  and Physical  examination  
 
o Physical examination will be performed,  which  must comprise a total body 
examination (general  appearance,  skin, neck, eyes, ears,  nose, throat,  lungs, heart, 
abdomen,  back,  lymph  nodes,  extremities,  and basic  nervous system). 
o Significant  findings  made  after the start of study  drug that meet  the definition of an 
Adverse Event  must  be recorded.  
 
• Performan ce status 
 
o Karnofsky  Performance Status  (KPS)  >70% 
 
 
 
Within  30 days of starting  treatment:  
 
• Che st  X-Ray  
• Pulmonary  function  tests  
• Cystosco py 
• Transuret hral Resection  
• ECG :A standard 12-lead ECG is to be performed during scr eening and significant  findings 
must  be recorded.  
• HBV testing 
o Hepatitis  B testing (HBV -DNA,  HBsAg,  HBsAb,  and HBcAb)  for all patients who meet 
the hepatitis  B risk criteria outlined in Section  6.1. 
o HBV D NA monitoring sh ould be done depending on the results  from serologic 
markers  and viral load as listed  in Table 9.3-3. 
 
• HCV testing 
 
o Hepatitis  C testing  (Quantitative  RNS-PCR)  for all patients who meet  the hepatitis  C 
risk criteria  outlined in Section  6.1. 
o Follow -up testing  will be performed,  as per the visit schedule,  only if the patient  has a 
history  or is positive at baseline,  or both. 
 
  
 
9.0TREA TMENT/ INTERVENTION PLAN 
Amended:  1/11/11  
Page  28 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 9.1 Phase  I Schedule  and Dose  Administration  
 
Table  9.1-1 Treatment  Drug  Dose  and Schedule  
D ose l evel Eve r olim us  Dose and schedule Gemcitabi ne Dose and  Schedule 
1 (starting dos e) 5 mg ever y other day 2000 mg tw ice w eekly 
2 5 mg dail y 2000 mg tw ice w eekly 
3 10mg daily 2000 mg tw ice w eekly 
 
All chemotherapy  will be administered in the outpatient  chemotherapy  unit. 
 
 
9.1.1  Dose  Escalation  Sche me  
 
3 dose levels  of contin uous Everolimus  (Everol imus dose le vels: Dose  level 1: 5 mg every  other  day, 
Dose  level 2: 5 mg daily,  and Dose  level 3: 10 mg daily)  in combination with a fixed dose  of 
intravesical  gemcitabine at a dose of 2000  mg twice  weekly  for 3 weeks  followed by a week  of rest 
from gemci tabine (there is no rest week from Everolimus),  and a second course of intravesical 
gemcitabine followed by a week  of rest from gemcitabine will be evaluated using  the DLT rules 
outlined below:  
 
 
 
  
Number  of subje cts  with 
DLT  
Action  
 
0 of 3 subjects Escalate  to next highest  dose  level and enroll 
up to 3 subjects  
 
1 of 3 subjects Enroll  up to 3 more  subjects  at the same  dose 
level 
 
1 of 6 subjects Escalate  to next highest  dose  level and enroll 
up to 3 more subjec ts 
2 or 3 subjects in the first 3 
subjects  De-escalate  to lower  dose level and enroll  up to 
6 subjec ts 
 
≥ 2 of 6 subjects De-escalate  to lower  dose level and enroll  up to 
6 subjec ts 
 
If 2 of the first 2 subjects have DLT, the enrollment  of a third subject at the same  dose  level is not 
necessary.  Similarly,  if 2 of 4 subjects or 2 of 5 subjects  have DLT, it is not necessa ry to enroll 
subsequent  subjects at the same  dose level.  
 
 
There will be no plann ed dose  level below  dose level 1. If ≥ 2 DLTs  occur  at dose level 1, then the 
study  will be terminated.  
 
There will be no plann ed dose  level beyond  dose  level 3. If no DLTs  occur at dose l evel 3, the 
Phase  II portion  of the trial will be init iated. 
Amended:  1/11/11  
Page  29 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
  
Patients  will be assessed for DLTs  up the completion of the 3rd cycle of treatment.  
 
9.1.2  Maximum  Tolerated  Dose  
 
The MTD  is the dose level at which  no more  than 1 out of 6 patients  experience DLT. 
If ≥ 2 subjects at the first dose level experience DLT, then the study  will be terminated  and the 
combination of Everolimus  at a dose of 5 mg every other  day with intravesical  gemcit abine at a dose 
of 2000  mg twice  weekly  will be considered unsafe in this population.  
 
Patients  will be observed for DLTs  through one cycle of treatment  (4 weeks) prior to dose esca lation 
for the next dose level.  No intrapat ient dose escalation will occur. DLTs  will be defined as follows, 
using  NCI Common  Terminology  Criteria for Adverse  Events  (CTCAE)  version  4.0: 
 
1) Any evidence of grade 3 or 4 toxicity  under  Renal  and Urinary  Disorders  in CTCAE  version 4.0. 
 
2)  Febrile  neutropenia (absolute  neutrophil  count (ANC))  < 1000/μL  plus oral temperature to 8.5°C)  
 
3)  Grade  4 neutropenia (ANC  <500 /μL) for ≥ 7 days 
 
4)  Other  grade  4 hematologic  toxicity  
 
5)  Other  nonhematologic  grade  3 or 4 treatment -related toxicity,  excluding n ausea/vomiting,  rash, 
untreated hyperlipidemia or grade  3 fatigue lasting ≤ 7 days. 
 
6)  Any nonhe matologic  toxicity  requiring  treatment  delay  for > 7 days during cycle 1. 
 
  
9.2 Phase  II Dose  Administration  
 
The dose  level of Evero limus for the Phase II Study  will be based  on the MTD  from Phase I part of 
the study,  administered continuously,  and intravesical  gemci tabine will be administered at a dose of 
2000  mg twice  weekly  for 3 weeks, f ollowed by a week of rest and a second course of intravesical 
gemcitabine,  followed by a week  of rest (there  is no rest week  for Everolimus,  only for gemcitabine). 
Everolimus  will be continued  for 12 months  in the patients  who achieve a CR after two courses  of 
gemcitabine.  Patients  demonstrating a CR (by cystoscopy  and cytology)  will be obser ved with serial 
cystoscopies every  3 months.  
 
All chemotherapy  will be administered in the outpatient  chemotherapy  unit.9.2.1 Interruption  or 
Discontinuation of Treatment  During Phase  II 
 
For patients  who are unable to tolerate the protocol -specif ied dosing  schedule,  dose a djustments  of 
Everolimus,  but not of gemcitabine,  are permitted.  If administ ration  of Everolimus  must  be 
interrupted because of unacceptable toxicity,  drug dosing  will be interrup ted or modified  accordi ng to 
rules  described in Section 9.1. Toxicity  will be assessed using the NIH-NC I CTCAE,  version 4.0 
(http://evs.nci.nih.gov/f tp1/CTCAE /CTCAE_4. 03_2010- 06-14_QuickReference_8. 5x11.pdf).  
If at any point  a patient  develops  any grade  3 toxicity  suspected to be related to gemcitabine, 
gemcitabine may be delayed for up to 14 days while  Everolimus  will con tinue  to be taken 
continuously.  If at any point  a patient  develops  any grade  4 toxicity  suspected to be related to 
 
A
mended:  1/11/11  
Page  30 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 gemcitabine,  the patient  will be taken off study. If a dose delay of gemcitabine greater  than 14 is 
 
 
Nonhem atological toxicity 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
required,  the patient  will be taken  off study.  
 
Patients  who are removed from study  due to withdrawal  of consent,  lost to follow -up, or 
administrat ive problems  should not be consider ed unevaluable and will be replaced.  
 
 
9.3 Phase  II Dose  Modifications  
 
There will be no dose modificatio ns for gemcitabine,  only for Everolimus.  
 
 
Table  9.3-1 Phase  II Everolimus  Dose  Modifications  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended:  1/11/11  
Page  31 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
  
Grade 2  
(except pn eumonitis – refer to Section 4.2)  
 
 
 
 
 
 
Grade 3  
(except hype rlipide mia*) 
(except pn eumonitis – refer to Section 4.2)  
 
 
Grade 4   
If the tox icity is tolerable to  the patient, maintain the same 
dose. If  the toxi city is intolerable to patient, interrupt 
Ev er o li mus un til reco very to grade ≤1. Then reintr oduce 
Ev er o li mus at  same dos e. 
If event returns to  grade 2,  then interr upt Ev erolimus until 
recovery to grade ≤1. Then reintroduc e  Ev er olimus at  the 
low er dose level. 
 
Interrupt Ever olimus until rec overy to grade ≤1. Then 
reintr oduce E verolimus at the low e r dose le vel. For 
pneumonitis, cons ider the us e of a short course of 
corticosteroids.  
 
Discont inue Everoli mus. 
Hematological  toxicity  
 
Grade 2 Th rombo cytopenia (platelets <75,  ≥50x109/L) 
 
Gr ad e 3 Th rombo cytopenia (platelet s <50, ≥ 25 x109/L) 
Gr ad e 4 Th rombo cytopenia (platelet s <25 x109/L) 
Grade 3 N eutrope nia (neutrophils < 1, ≥0.5 x109/L) 
 
 
 
 
 
 
Grade 4 N eutrope nia (neutrophils < 0.5 x109/L) 
 
 
 
 
Grade 3 febr ile neutropen ia (not life-threat ening) 
 
 
 
 
 
Grade 4 febr ile neutropen ia ( life- threate ning)  
 
Interrupt Ever olimus until rec overy to grade ≤1 (>75  x109/L). 
Then reintroduce Ev erol i mus  at initia l dos e. 
If throm bo cytopenia return s to grade 2, interrupt Everol imus 
until reco very to grade ≤1.  Then reintroduce Everoli mus at 
the low er dos e level.  
 
Interrupt Ever olimus until rec overy to grade ≤1 (plat elets ≥  
75 x109/L). Then resume Ever olimus  at one dose le vel 
low e r. If grade 3 thromboc ytopenia recurs, discont inue 
Ev er o li mus 
 
Discont inue Everoli mus. 
 
Interrupt Ever olimus until rec overy to grade ≤1 (neutr ophils 
≥1.5 x 109/L). Then resume E verolimus at the initial  dose. If  
ANC returns to grade 3,  hold Ev eroli mus unt il the ANC ≥ 1.5 
x 109/L. Then resume Ev er olimus dos ing at  the low er dos e 
level. Dis continue pat ient from  study therapy for a third 
episode of grade 3 ne utropenia. 
 
Interrupt Ever olimus until rec overy to grade ≤1 (neutr ophils 
≥1.5 x 109/L). Then resume E verolimus at the low e r dose 
level. If  grade  3 or gra de 4 ne utrope nia occurs despite this  
dose r eduction, disconti nue Everoli mus. 
 
Interrupt Ever olimus until res olution of fever and n eutropenia 
to grade ≤1. Hold further Ev erolimus until the A NC 
≥1,50 0/mm3 and fever has reso lved. Then resume  
Ev er o li mus at  the low er dos e lev el. If  febrile neutrop enia 
recurs, disc ontinue Ever olimus. 
 
Discont inue Everoli mus. 
Any hema tological  or nonh ematological  toxicity 
requiring  interrupti on for ≥ 3 weeks  
Discont inue Everoli mus 
 
 
*Grade 3 hyperlipidemia  (hypercholesterolemia  and/or  hypertriglyceridemia)  should be managed 
using  medical  therapies  
 
All interruptions  or changes to study  drug administration must be record ed. 
 
  
9.3.1  Monitoring  of Everolimus  Suspected  Toxicities  
 
 
Amended:  1/11/11  
Page  32 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 Patients  whose  treatment  is interrup ted or permanently  discontinued due to an adverse event  or 
abnormal  laboratory  value suspect ed to be related to Everolimus  must be followed at least weekly 
until the adverse event  or abnormal  laboratory  resolves  or returns to grade 1. If a patient  requires  a 
dose  delay  of >21 days from the intended day of the next scheduled dose, then the patient must be 
discontinue d from the study. 
 
9.3.2  Management  of Stomatitis/Oral Muco sitis/Mouth  Ulcers  
Stomatitis/oral  mucositis/ mouth ulcers  due to Everolimus  should be treated using  local supportive 
care.  Please  note that investigators  in earlier  trials have described the oral toxicities  associat ed with 
Everolimus  as mouth  ulcers,  rather  than mucositis  or stoma titis. If your examination reveals  mouth 
ulcers  rather  than a more  general  inflammation of the mouth,  please classify  the adverse event  as 
such. Please follow  the paradigm  below  for treatment  of stomatitis/oral  mucositis/mouth ulcers:  
 
1.  For mild toxicity  (grade  1), use conservative  measures  such as non-alcoholic  mouth  wash  or 
salt water (0.9% ) mouth wash  several  times  a day until resolution.  
2.  F or  more  severe  toxicity,  (such  as grade 2, in which  case patients  have pain but are a ble to 
maintain adequate oral alimentation,  or grade 3, in which  case patients  cannot  maintain  
adequate oral alimentation),  the suggested treatments  are topical  analgesic mouth  treatments  
(i.e., local  anesthetics such  as benzocaine,  butyl amin obenzoate,  tetracaine 
hydrochlor ide, menthol,  or phenol)  with or without  topical  corticosteroids,  such as 
triamcinolone oral paste 0.1%  (Kenalog  in Orabas e®). 
3.  Agents  cont aining hydrogen peroxide,  iodine,  and thyme  derivatives  may tend to worsen  mouth 
ulcers.  It is preferable to avoid  these  agents.  
4.  Antifungal  agents  must be avoided unless  a fungal infection is diagnose d. In particular,  systemic 
imidazole  antifungal  agents (ketoc onazole,  fluconazole,  itraconazole,  etc.) should be avoided in 
all patients due to their strong  inhibition of Everolimus  metabolism,  thereby  leading  to higher 
Everolimus  exposures.  Therefore,  topical  antifungal agents  are preferred if an infection is 
diagnosed.  Similarly,  antiviral agen ts such as acyclovir should  be avoided unless  a viral infecti on 
is diagnos ed. 
Note:  Stom atitis/oral mu cositis  should  be appropriately  graded using  the functional  grading  given  on 
the NCI-CTCAE,  version 4.0. 
 
9.3.3  Management  of Hype rlipide mia  and Hyperg lyce mia 
 
 
Treatment  of hyperlipidemia should take into account the pretreatment  status  and dietary habits. 
Blood tests to monitor  hyperlipidemia must be taken  in the fasting  state.  Grade 2 
hypercholesterolemia  (>300  mg/dL  or 7.75 mmol /L) or grade  2 hypertriglyceridemia (>2.5  x ULN) 
should  be treated  with a 3-hydroxy -3-methyl -glutaryl ( HMG) -CoA reductase inhibitor  (e.g., 
atorvastatin,  pravastatin)  or appropriate  lipid-lowering medication,  in addition to diet. Patients  should 
be monitored clinically  and through serum  biochemistry  for the development  of rhabdomyo lysis and 
other  adverse events  as required in the product  label/data sh eets for HMG -CoA reductase inhibitors.  
 
 
 
Amended:  1/11/11  
Page  33 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 Note:  Concomitant  therapy  with fibrates  and an HMG- CoA reductase in hibitor  is associated with an 
increased risk of a rare but serious  skeletal  muscle toxicity  manifested by rhabdomyolysis,  markedly 
elevated creatine kinase (CPK)  levels and myoglobinuria,  acute  renal  failure,  and, sometimes,  
death.  The risk versus  benefit  of using  this therapy should  be determined for individ ual patients 
based on their risk of cardiovascular  complicati ons of hyperlipidemia.  
 
Grade  3 hyperglycemia has been ob served  in patients  receiving Everolimus  therapy.  In many  cases 
in study  Everolimus  C2222,  the affected  patients  had an abnormal fasting  glucose at baseline. 
Monitoring of fasting  serum glucose is recommended prior to the start of everolimus  therapy  and 
periodically  thereafter.  Based  on this finding,  it is suggested t hat optimal  glucose con trol should b e 
achieved before starting  a patient  on Everoli mus and should be monitored during  Everoli mus 
therapy.  
 
 
 
9.3.4  Management  of non-infectious  pneumonitis  
 
Both asympt omatic  radiological  changes (grade 1) and symp tomatic  noninfectious  pneumonitis 
(grade  2 = not interfering with activities  of daily living, or grade  3 = interf ering with activities  of daily 
living  and oxygen  indica ted) have  been  noted  in patients  receiving Everolimus  therapy. 
Noninfectio us pneumonitis  has been  associat ed with Everolimus  and other  mT OR  inhibitors.(40)  In 
order  to monitor  for asymptomatic  (grade  1) pulmonary infiltrates,  a chest X-ray is required  if a CT 
scan of chest is not used for bimonthly  disease evaluations.  Additional  chest CT scans may be 
performed,  when clinic ally necessa ry. If noninfectious  pneumonitis  develops,  a consultation  with a 
pulmonologist  should be considered.  If the patient develops  grade 3 pneumonitis,  treatment  with 
Everolimus  should  be interrupted and the patient  should be treated  as medically  indicated (short 
course corticosteroids,  oxygen,  etc.). 
Manageme nt of no ninfectious  pneumonitis  suspected  to be associated with Everolim us and dose 
modificatio ns instructions are provided below . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended:  1/11/11  
Page  34 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 Table  9.3-2 Managem ent of Non-Infectious  Pneumonitis  
 
Worst  Grade  
Pneumonitis  Required  Inves tigations  Manageme nt of 
Pneumonitis  Eve r olim us  Dos e  Adjustment  
Grade 1  CT scans  with lung w indow s and 
pulmonary function testing 
includi ng: spi rometry, DLCO, and 
room air O 2 saturation at  rest. 
Repeat chest  x-ray /CT scan  
every 2 cycles until retur n to 
baseline. No  spe cific th erapy is 
required Adminis ter 100 % of  Ev er o li mus dose.  
Grade 2  CT scan  with lung w indow s and 
pulmonary function testing 
includi ng: spi rometry, DLCO, and 
room air O 2 saturation at  rest. 
Repeat eac h subs equent cycle 
until retur n to ba seline. C onsider 
bronc hoscopy *  Symptomatic  only. 
Prescribe 
corticoster oids if 
coug h is 
troubl esome.  Reduce Ever olimus dose until recover y to 
≤ grade 1.  Everoli mus may also be 
interr upted if symptoms ar e troub lesome. 
Patients  w ill be withdrawn from the stu dy 
if they fail to recover to ≤ grad e 1 w ithin 3 
weeks. 
Grade 3  CT scan  with lung w indow s and 
pulmonary function testing 
includi ng: spi rometry, DLCO, and 
room air O 2 saturation at  rest. 
Repeat eac h subs equent cycle 
until return to baseline. 
Bronc hoscopy is recomm ended * Prescribe 
corticoster oids if 
infective or igin is 
ruled out.  Taper  as 
medi cally indicated. Ho ld E verolimus until recover y to ≤ 
grade 1. May re start protocol  treatment 
within 2 weeks  at a reduc ed dose (by 
one level) if ev idenc e of clinical b enefit.  
Patients  w ill be withdrawn from the study 
if they fail to recover to ≤ grad e 1 w ithin 2  
weeks. 
Grade 4  CT scan  with lung windows and 
required pulmonary functi on 
testing include s: spiromet ry, 
DLCO, and r oom air O 2 saturation 
at rest. Repeat  each subse quent 
cycle unt il retur n to base line. 
Bronc hoscopy is recomm ended *. Prescribe 
corticoster oids if 
infective or igin is 
ruled out.  Taper  as 
medi cally indicated. Discont inue Everoli mus. 
*A bronc hoscopy w ith biopsy and/or br oncho alveolar lavage is  rec o mme nded.  
 
 
Manageme nt of hepatitis  reactivation  
 
9.3.5  Management  of Hepatitis B  
 
Table 9.3-3 provides  details  of moni toring  and prophylactic  therapy  according  to the baseline results 
of viral load and serologic  markers  testing.  
 
 
Table  9.3-3 Action  to be taken  for Positive  Base line  Hepatitis  B Results  
 
Test  R esult  R esult  R esult  R esult  R esult  
 
HBV -DNA   
+  
+ or -  
-  
-  
- 
 
HBsAg   
+ or -  
+  
-  
-  
- 
 
HBs Ab  
+ or -  
+ or -  
+ 
 
and no prior HBV  
vaccination   
+ or -  
- 
 
or + with prior HBV  
vaccination  
 
HBc Ab  
+ or -  
+ or -  
+ or -  
+  
- 
 
Reco mm endation  
Pr op hylaxis treatment  shou ld 
be started 1 -2 weeks p rior to   
No  pr ophy laxis  
No  spe cific act ion 
 
Amended:  1/11/11  
Page  35 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
  
Test  R esult  R esult  R esult  R esult  R esult  
 first dose of  study drug 
 
Monitor HBV -DNA  
appro ximately every 4- 8 
weeks  
Monitor HBV -DNA appro ximately 
every 3-4 w eeks  
 
 
In cancer pa tients  with hepatitis  B, whether  carriers  or in chronic state, use of antivi rals during 
anticancer  therapy  has been shown to reduce  the risk of hepatitis B virus (HBV)  reactivation and 
associat ed HBV morbidity  and mortality.(41)  
 
Antiviral prophylaxis  therapy  should  continue  for at least 4 weeks  after last dose of study drug.  
 
For hepatitis  B reactivation,  definiti on, and management  guidelines,  see Table  9.3-4 Guidelines  for 
manageme nt of hepatitis  B. 
 
Table  9.3-4 Guidelines  for Manag ement  of Hepatitis B  
 
HBV reactivation  (with or without  clinical  signs  and symptoms)*  
For patients  w ith baseline 
results:  
Positive HBV -DNA  
OR 
positi ve HBsAg  
-------------------- ------------------ 
reactivat ion is  defined as:  
[Increase of  1 log in HBV -DNA  
relati ve to baseline HBV-DNA  
value OR n ew  appearance of 
measur able HBV-DNA ]  
AND 
ALT elevation x 5 ULN Treat:  Start  a secon d anti viral 
AND 
Interrupt study drug administration until resolution:  
• ≤ grade 1 ALT (or basel ine ALT, if > grade 1) and  
• ≤ basel ine H BV-DNA  le vels 
If resolution occurs  w ith in ≤ 28 days  study drug shoul d be re-started at 
one dose low er , if availa ble. (see T able 9.1-1 – Treatment  Drug  Dose 
and Sc hedu le) If the patient is alr eady rec eiving the l ow est dose of  study 
drug ac cording to the protoco l, the patient s hould restart  at the same 
dose after  resolution. Both ant iv iral t herap ies shou ld continue at least 4 
weeks after  last dose of  study drug.  
If resolution oc curs >  28 days Patients sh ould disc ontinue study drug but 
conti nue both antivi ral ther apies at least 4 w eeks after  last dose of  study 
drug.  
For patients  w ith baseline 
results:  
Negat ive HBV -DNA  and HBsAg 
AND [Positive HBs  Ab (w ith no pri or 
histo ry of vacci nation against 
HBV),  OR positive HBc Ab]  
-------------------- ----------------- 
reactivat ion is  defined as:  
New  a ppearance of  
measur able HBV-DNA  Treat : Start  first antiviral medication  
AND 
Interrupt study drug administration until resolution:  
• ≤ basel ine H BV-DNA  le vels 
If resolution occurs  w ith in ≤ 28 days  study drug shoul d be re-started at 
one dose low er , if availa ble. (see T able 9.1-1 – T reatment  Drug Dos e 
and Sc hedu le) If the patient is alr eady rec eiving the l ow est dose of  study 
drug ac cording to the protoco l, the patient s hould restart  at the same 
dose after  resolution. Antiv iral therap y shou ld contin ue at least 4 w eeks 
after  last dose of study dr ug. 
If resolution oc curs >  28 da ys Patients shoul d disc ontinue study drug but 
conti nue antivira l ther apy at least 4 w e eks after  last dose of study drug.  
* All reactivations of he patitis B are to be recorded as gra de 3 (CTCAE v 3.0 Metabol ic Labora tory/Other: Viral 
Re-activation ), unless  considered life threateni ng by the investi gator; in whic h case they sh ould be r ecord ed as 
grade 4 (CTCAE v 3.0 Metabol ic Labora tory/Other: Viral R e-activation). Date of v iral reac t ivat ion is the date  on 
which both  DNA and ALT  criteria were  met (e.g. for  a patient w ho was HBV-DNA positive o n 01- JAN-10 and 
whose ALT reached ≥ 5  × UL N on 01-A PR-10, the date of viral r eactivation is 01-APR-10). 
 
9.3.6  Monitoring  for Hepatitis  C 
Amended:  1/11/11  
Page  36 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 The followi ng two categories  of patients  should  be monitored every  4–8 weeks  for HCV reactivation:  
 
• Patients  with detectable HCV RNA-PCR test at baseline.  
 
• Patients  known to have  a history  of HCV infection,  despite a negative  viral load test at baseline  
(including those that were treated  and are consid ered ‘cured’)  
 
For definition of hepatitis  C reactivation and the management guidelin es, see Table  9.3-5. 
Guidelines  for management  of hepatitis  C. 
 
Table  9.3-5 Guidelines  for manage ment  of hepatitis C  
 
HCV reacti vation* 
For patients  w ith baseline res ults: 
Detecta ble HCV-RNA ,  
 
reactivat ion is  defined as:  
ALT elevation x 5 ULN Discont inue stud y drug 
For patients  w ith baseline res ults: 
Know led ge of past he patitis  C infec tion w ith no detect able HCV -RNA ,  
 
reactivat ion is  defined as:  
New  a ppearance of  detectabl e HCV -RNA  Discont inue stud y drug 
* All reactivations of he patitis C are  to be  recorded as gra de 3 (CTCAE v 3.0 Metabol ic Labora tory/Other: Viral 
Re-activation ), unless  considered life threateni ng by the investi gator; in whic h case they sh ould be r ecord ed as 
grade 4 (CTCAE v 3.0 Metabol ic Labora tory/Other: Viral R e-activation).  
 
 
9.4 Concomitant  thera py 
 
Patients  will be instructed not to take any additional  medicat ions (inclu ding over-the-counter  products)  
during the course of the study without  prior consulta tion with the investigato r. At each visit, the 
investig ator will ask the patient  about any new medications  he/she  is or has taken after the start of the 
study  drug.  
 
All Concomitant  medications/Significant  non-drug therapies  taken ≤30 days prior to start and after 
start of study drug,  including physical therapy  and blood transfusions, sh ould be recorded.  
 
The followi ng restrictio ns apply  during  the entire duration of the study: 
 
• No other  investigation al therapy  should  be given to patients.  
 
• No anticancer  agents  other than the study  medication  should be given to patients.  If such agen ts 
are required for a patient, then the patient must  first be withd rawn from the study. 
• Co-administration  with strong  inhibi tors of CYP3 A4 (e.g.,  ketoconazole,  itraconazole,  ritonavir)  or 
P-gp should  be avoided  
 
• Seville  orange,  star fruit, grapefruit,  and their juices affect  P450 and P- gp activity. Concomitant 
use should be avoided  
• Co-administration  with moderate CYP3A4  inhibitors  (e.g.,  erythromycin, fluconaz ole) or P-gp 
inhibitors  should be used with caution. If patient  requires  co-a dministrati on of moderate CYP3A4  
Amended:  1/11/11  
Page  37 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 inhibitors  or P-gp inhibit ors, reduce  the dose  of Everolimus  to half the currently  used dose. 
Additional  dose reducti ons to every  other  day may be required  to manage toxicities.  If the 
inhibitor  is discontinued,  the Everolimus  dose sho uld be returned to the dose used  prior to 
initiation  of the moderate CYP3A4 /P-gp inhibit or. 
• Avoid  the use of strong  CYP3A4  inducers. 
 
• No chronic  treatment  with systemic steroids  or other immun osuppressive agents  (at a dose 
equivalent  or greater  than 20 mg prednisone per day).  Topical  or inhaled  corticostero ids are 
allowed.  
• Everolimus  may affect t he response to vaccinations, making  the response to the vaccination le ss 
effective. Live vaccines should be avoided while  a patient  is treated  with Everolimus.  
 
• Oral anticoa gulants  such as warfarin are CYP2 C9 substrat es and, as such, no interaction  with 
Everolimus  is expected.  However,  drug-drug interaction stud ies between macrolide antibiotics 
and warfarin  have  produced  mixed  outcomes  and the disparity  in these findings  has led to the 
conclusion t hat multiple  factors  may alter the clearance  of warfarin.  The co-administ ration  of 
Everolimus  and oral anticoagulants  is possi ble but should be subject  to verification  of 
coagulation (INR)  once  steady  state is reached ( after one week’s  treatm ent). 
 
A comprehensive list of cytochrome P450 isoenzymes  and CYP3A4  inhibitors,  inducers, and 
substrates  can be found  at http://medicine.iupu i.edu/flockhart. This websi te is cont inually revised 
and should  be checked frequently  for updates.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended:  1/11/11  
Page  38 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 Table  9.4-1 Clinically Relevant  Drug  Interaction:  Substrates,  Inducers,  and Inhibitors  of 
Isoenz yme CYP3A4.  
 
 
SUBS TRATES 
 
Antibiotics:  
 
Clarithromycin,  erythromycin,  telithromycin   
Calcium  channel  blockers:  
 
Amlodipine,  diltiazem,  felodipine,  lercanidipine, 
nifedipine,  nisoldi pine, nitrendipine,  verapamil  
 
Anti-arrhythmics:  
 
Quinidine   
HM G  CoA reductase  inhibitors:  
 
Cerivastatin,  lovastatin,  simvastatin  
 
Benzodiaz epines:  
 
Alprazolam,  diazepam,  midazolam,  triazolam   
Ste roid  6beta -OH: 
 
estradiol,  hydrocortison e, progester one, testoste rone 
 
Immune  modulators:  
 
Cyclosporine,  tacrolimus  (FK506)   
Miscellaneous:  
 
Alfentanil,  aprepitant,  aripirazole,  buspirone,  cafergot, 
caffeine,  cilostazol,  cocaine,  codeine -N-demet hylation, 
dapsone,  dexamethason e, dextromet horphan, 
docetaxel  domperidone,  eplerenone,  fentanyl, 
finasteride,  Gleevec/im atinib, halope ridol,  irinotecan,  
LAAM,  lidocaine,  methadone,  nateglinide,  onda nsetron, 
pimozide,  propranolol,  quetiapine,  quinine,  risperidone, 
salmeterol,  sildenafil,  sirolimus,  sorafenib,  sunitinib, 
tamoxifen,  taxol, terfenadine,  torisel, trazodone, 
vincristine, zaleplon,  ziprasidone,  zolpidem   
HIV Antiv i rals: 
 
Indinavir,  nelfinavir,  ritonavir, saqui navir 
 
Prokinetic:  
 
Cisapride  
 
Antihistamines:  
 
Astemizole,  chlorphenir amine,  terfenadine  
 
INDUCERS  
 
Barbiturates,  carbamazepine,  glucocorticoids,  modafinil,  oxcarbazepine,  phenobarbi tal, phenytoin, 
pioglitazo ne, rifabutin,  rifampin,  St. John’s  wort, troglitazone,  efavirenz,  nevirapine  
 
INHIBITO RS 
 
Strong  inhibitors:  
 
indinavir,  nelfinavir,  ritonavir, clarith romycin, itraconazole,  ketoconazol e, nefazodon e, saquinavir, 
telithromycin,  
 
Posaconaz ole (Krishna  et al, 2009)  
 
 
Moderate  inhibitors:  
 
aprepitant,  diltiazem,  erythromycin,  fluconazole,  grapefruit  juice,  verapamil,  
 
 
Weak  inhibitors:  
 
Cimetidine,  
 
Seville  orange (Malhotra  et al, 2001) 
 
Amended:  1/11/11  
Page  39 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
  
Unclassified  as per the Indiana  University  DDI listing:  
 
Ciprofloxacin,  delaviridine,  trolean damycin, mibefradil,  amiodarone,  chloramphenicol, 
diethyldithi ocarbamate,  fluvox amine, starfru it, gestodene,  imatinib,  mifepristone,  norfloxacin, 
norfluoxetine,  voriconazole*  
 
Based on http:// medic ine. iupui.ed u/clinphar m/ddis/ta ble.asp as  of Dec ember 01, 2009  
*Voriconazole (unclassified as  per the Indiana  Unive rs ity DDI table)  Strong i nhibitor  according  to the 
following reference: (http://www.nature. com/c lpt/ journa l/ v8 0/n5/pdf/clpt2006438a.pdf)  
 
 
 
Table  9.4-2 Clinically Relevant  Drug  Interactions Mediated  by P- gP 
PgP Substrates  PgP Inhibitors  in v ivo PgP Inducers  
digoxin,  
fexofenadine,  indinavir, 
vincristine, colchicine, 
topotecan,  paclitaxel  amiodarone,  azithromycin,  
captopril,  carvedilol, 
clarithromycin,  conivapt an, 
cyclosporine, diltiazem, 
elacridar,  erythromycin, 
felodipine,  (GF120918), 
itraconazol e, ketocoanzole, 
lopinavir,  (LY335979), 
mibefradil,  nifedipine, 
nitrendipine,  (PSC833), 
quinidine,  ranolazine, 
ritonavir , talinolol,  valspo dar, 
verapamil  rifampin,  St John’s  wort 
  
Reference:  
 
Internal  Clinical Pharmacology Drug -drug interaction (DDI)  memo,  updated Dec. 2, 2009,  which 
summarizes  DDI  data  from  three  sourc es  including  the  FDA’s  “Guidance  for  Industry,  Drug 
Interaction  Studies,  the  University  of  Washington’s  Drug  Interacti on  Database,  and  Indiana 
University  School  of Medicine's  Drug Interaction Table."  
 
NOTES: http://www.fda.g ov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidance  
s/UCM0721 01.pdf  
 
**This  list of clinically  relevant  drug interactions  is updated as of December  02, 2009**  
 
 
10.0EVAL U ATION DURING TREA TMENT/INTER VENTION  
 
  
 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  40 of 62  
  
Phase  I Visit  Schedule  *continued  on next page*  
 Screening  Pre-Treatment 
Eval uations Cycle  1 
(Weeks  +2 days)  Cycle  2 
(Weeks  +2 days)  28-Day Cycles  (+7 days)  
Within  
30 Days  Within  
14 Days  Within  
7 Days  1 2 3 41 5 6 7 81 3 4 5 6 7 8 9 10 11 12 
Informed Consent X                      
ECG X                      
Pulmonary  Funct ion 
Tests  X                     
Urine Cu lt ure  X                     
Urine Cytology   X           X   X   X   X 
Cyst oscopy  X           X   X   X   X 
Transurethral  Res ecti on  
(TUR)4  X                     
Che st  X -Ray  X           X   X   X   X 
HBV -DNA, HBsAg, HBs Ab, 
HBs Ab, HCV -RNA-PCR2  X                     
HBV  DNA, HCV  RNA-PCR3  X   X   X     X          
Karnofsky  Performance  
Status    X  X X X X X X X X X X X X X X X X X X 
Urinalysis    X                    
Complete History    X                    
Physical Exam    X  X X X X X X X X X X X X X X X X X X 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  41 of 62  
 Phase  I Visit  Schedule  (Cont .)  
 Screening  Pre-Trea tme nt 
Eval uations Cycle  1 (Weeks  
+2 days)  Cycle  2 (Weeks  
+2 days)  28-Day Cycles  (+7 days)  
Within  30 
Days  Within  
14 Days  Within  7 
Days  1 2 3 41 5 6 7 81 3 4 5 6 7 8 9 10 11 12 
Vital  Signs    X  X X X X X X X X X X X X X X X X X X 
Com plete Blood Count 
(hemoglobin,  hematocrit, 
platelets,  total  white  blood  ce ll 
count  (W B C) and differ entia l)  5
   X    X    X  X X X X X X X X X X 
Compr ehensive Panel 
(sodium,  potassium,  chloride, 
bicarbonate,  calcium, glucose, 
creatinine,  blood  urea n it rogen, 
albumin,  tota l  protein,  SGOT 
(AST ), SGPT  (ALT),  total  
bilirubin,  alkaline  phosphatase)  
5   X    X    X  X X X X X X X X X X 
Uric Acid    X    X    X  X X X X X X X X X X 
Phosphorus    X    X    X  X X X X X X X X X X 
Serum Lip id Profile 
(triglycerides,  total  choleste rol, 
HDL,  and LDL)    X    X    X  X X X X X X X X X X 
Serum Preg nancy Te st    X                   
Collect ion of Ti ssue  
Speci men    X                   
Toxicity  Assess ment       X X  X X X X X X X X X X X X X X 
Gemcit abine     X X X  X X X            
Everolimus      X X X X X X X X X X X X X X X X X X 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  42 of 62  
 11 w e ek of  rest f rom ge mc ita bine. There is no  w eek of  rest from Everoli mus, w hic h is tak en conti nuously. 
 
2All patie nts shoul d be scr eened for  hepatitis  ris k factors  and an y past i llnesses of  hepat itis B and he patitis C.  It is high ly recom mende d that  patients  positiv e HBV -DNA or 
HBsAg are tr eated prophylac tically with an an tiv iral for  1-2 w eeks p rior to  receiv ing stu dy drug (see Sec tion 3.2.7).  The antiviral treat ment should continue throu ghout the entire 
study period and for  at least 4 w e eks after  the last dos e of study drug. Pat ients with viral hepatitis C risk  factors  should be screened for  HCV  RNA -PCR. 
 
3 Patients on an tiviral  proph ylaxis treatment  or positi ve HBV antibodie s sho uld be tested for  HBV-DNA  accordi ng to study visit s chedule. Pati ents w ith positive HCV-RNA  PCR  
or a histor y of past infecti on, even if t reated and c onsidered ‘cur ed’ – should be follow ed by HCV -RNA  PCR acco rding to v isit schedu le. 
 
4During f ollow -up, if a suspic ious or pos itive cystoscopy/cytol ogy is fou nd, a TUR will be performed no late r than 4  w eek s. 
 
5All blo od w ork w ill be done month ly. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  43 of 62  
  
Phase  II Visit Schedule  *continued  on next page*  
 Screening  Pre-Treatme nt 
Eval uations Cycle  1 
(Weeks  +2 
days)  Cycle  2 
(Weeks  +2 
days)  28-Day Cycles  (+7 days)  
Within  
30 Days  Within  
14 Days  Within  
7 Days  1 2 3 41 5 6 7 81 3 4 5 6 7 8 9 10 11 12 15 18 21 24 
Informed Con sent  X                          
ECG  X                          
Pulm onary Function Test s   X                         
Urine  Culture  X                         
Urine  Cytology   X           X   X   X   X X X X X 
Cystosco py  X           X   X   X   X X X X X 
Transurethral  Resection 
(TU R)4  X                         
Chest X-Ray  X           X   X   X   X X X X X 
HBV -DNA, HBsAg, HBs 
Ab, HBs Ab, HCV-RNA - 
PCR2  X                         
HBV  DNA, HCV  RNA-PCR3  X   X   X     X              
Karnofsky  Performance  
Status    X  X X X X X X X X X X X X X X X X X X X X X X 
Urinalysis    X                        
Comple te History   X                        
Physical  Ex am    X  X X X X X X X X X X X X X X X X X X X X X X 
Phase  II Vis it Schedule  (Cont.)  
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  44 of 62  
  Screening  Pre-Treatment Evalu ations  Cycle 1  (Weeks  
+2 da ys)  Cycle 2  (Weeks  
+2 da ys)  28-Day Cycles  (+7 days)  
Within  
30 Days  Within  
14 Days  Within  
7 Days  1 2 3 41 5 6 7 81 3 4 5 6 7 8 9 10 11 12 15 18 21 24 
Vital  Signs    X  X X X X X X X X X X X X X X X X X X X X X X 
Com plete Blood Count 
(hem oglobin,  hematocrit, 
platelets,  total  white  blood 
cell count  (W B C) and 
d ifferen ti al)  5
   X    X    X  X X X X X X X X X X X X X X 
Compr ehensive Panel  
(sodium,  potassium,  chloride, 
bicarbonate,  calcium,  
glucose,  creatinine,  blood 
urea  nitrogen,  albumin,  total 
prote in,  SGOT (AST), SGPT 
(ALT ), total  bilirubin,  alkaline 
phosphatas e)  5
   X    X    X  X X X X X X X X X X X X X X 
Uric Acid    X    X    X  X X X X X X X X X X X X X X 
Phosphorus    X    X    X  X X X X X X X X X X X X X X 
Serum Lip id Profile 
(triglycerides,  total 
choleste rol,  HDL,  and LDL)    X    X    X  X X X X X X X X X X X X X X 
Serum Preg nancy Te st    X                       
Collect ion of Ti ssue  
Spec imen    X                       
Toxicity  Assess ment       X X  X X X X X X X X X X X X X X X X X X 
Gemcit abine     X X X  X X X                
Everolimus      X X X X X X X X X X X X X X X X X X     
 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  45 of 62  
 11 w e ek of  rest f rom ge mc ita bine. There is no  w eek of  rest from Everoli mus, w hic h is tak en conti nuously. 
 
2All patie nts shoul d be scr eened for  hepatitis  ris k factors  and an y past i llnesses of  hepat itis B and he patitis C.  It is high ly 
recomme nded that patients positive HBV -DNA  or HBsAg  are tr eated p rophyla ctically with an anti viral for 1-2 w ee ks prior to 
receiv ing stu dy drug (see Sec tion 3.2.7).  The antivi ral treat ment should continu e throughout the entire study period and for 
at least 4 w eek s after  the last dose of  study drug. Patients  with viral hepatit is C risk factors  shoul d be scr eened for  HCV  
RNA -PCR.  
 
3 Patients on an tiviral  proph ylaxis treatment  or positi ve HBV antibodie s sho uld be tested for  HBV-DNA  accordi ng to study 
visit sche dule. Patients  with positive H CV-R NA PCR or a h istory of past infection, ev en if treated an d considered ‘ cured’ – 
shou ld be foll ow ed by H CV-RNA PCR acco rding to visit sche dule. 
 
4During f ollow -up, if a suspic ious or pos itive cystoscopy/cytol ogy is fou nd, a TUR will be performed no late r than 4  w eek s. 
 
5All blo od w ork w ill be done month ly the first  12 months, the n ever y three months for  one ye ar. 
 
 
 
 
11.0TOXICITIES/SIDE  EFFECTS 
 
Known Undesirable  Side Effects  of Everolimus  
 
Overall,  the most  frequent  adverse effects  suspected  to be re lated to Everolimus  have  been 
stomatitis, r ash, anemia,  fatigue,  asthenia,  diarrhea, anorexia,  nausea,  hypercholeste rolemia, 
mucosal  inflammation,  vomiting,  hypertriglycerid emia,  cough,  peripheral  edema,  dry skin, epistaxis, 
pruritus,  and dyspnea.  The most common  grade 3 or 4 adverse reacti ons suspected to be related to 
treatment  were  anemia,  infectio ns, hyperglycem ia, stomatitis, fatigue,  lymphopenia, 
hypercholesterolemia,  pneumonitis,  and elevated gamma -glutamyltransferase conc entrations.  
 
The princip al DLT in Phase  1 trials has been grade 3 stomatitis.  
 
Hyperlipidemia was reported as a serious  adverse reaction.  It is a recognized side effect of 
rapamycins.  Use of lipid-lowering drugs  should  be associat ed with dieta ry recomme ndations. 
Monitoring of blood lipid levels  requires  patients  to be fasting  so that this aspect must  be verified 
when interpreting  resul ts. 
 
Hyperglyc emia was reported as a serious  adverse reaction.  Similarly,  the fasting  state of patien ts 
should  be verified  when  interpreting results. 
 
Pneumonitis  is a recog nized adverse  effect  of rapamycins (sirolimus,  temsirolimus,  and everolimus). 
Numerous  case reports  in the literat ure suggest  that rapamy cin-associat ed pneumonitis  is relatively 
unaggressive,  limited  in extent,  and reversible upon  drug discontinuation.  The term ‘pneumonitis’  is 
used  here to describe no ninfectious, nonmalignant  infiltration  in the lungs,  which  is evident 
radiologic ally. More  precise diagn osis should  follow histocytological  examination following lung 
biopsy,  generally  during  bronchosc opy that may or may not be symptoma tic. 
 
In oncology  studies  with Everolimus,  severe  pneumonitis  susp ected as drug-related has been 
reported  as a serious  adverse event  on 13 occasions  and additionally  in the following  associat ed 
preferred terms,  includi ng acute  respiratory  distress syndrome (n=2),  alveolitis  (n=1)  and allergic 
alveolitis  (n=1), interstitial  lung disease (n=10),  lung infiltration (n=23),  cryptogenic  organizing 
pneumonia,  lung consolidation,  pulmonary  alveol ar hemorrh age, pulmonary  toxicity,  and pulmonary  
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  46 of 62  
 fibrosis  (n=1, each).  One fatal case of drug- related pneumonitis  was reported for a patient  with 
metastatic  infiltrating  ductal carcin oma of the breast  treated with 10 mg/day,  which  developed 
approximat ely 2 months  after starting  Everolimu s. Cytologies  for both the pleural  and pericardial fluids  
were  positive  for malignancy.  The death  was conside red possibly  related  to the underlying  late stage 
tumor  and study  drug.  Addition ally, 1 patient treated  with 10 mg/day  died due to severe  acute 
respiratory  distress syndrome and septic  shock. Thoracic  computed tomography  (CT) scan 
demonstrated condensa tion in the majority  of the left lower  lobe and frosted glass  appearance in the 
left upper  lobe, lingula,  and right lung. 
 
Along with the cases  of noninfectious pneumonitis,  serious opportunistic  infectio ns have also been 
reported  in cancer  patien ts treated  with Everolim us: mycobacterium, aspergillus,  and fatal candida l 
sepsis, and fatal pneumocystis  carinii, in particul ar. Because Everolimus,  as other  rapamycins, 
inhibits  proliferation of activated lymphocytes  and reduces  neutrophil  counts, treatment  with 
Everolimus  must  be considered as predisposing patients  to the risk of infection.  This risk will b e 
higher  in patients severe ly immuno compromised because  of their underlying disease and/or  co- 
medications.  Outcome  may be fatal in case of serious  infections. 
 
A reduction  in blood  cell counts  is frequent  when Everolimus  therapy  is initiated.  Without clinical 
significance  and infreque ntly, anemia and thrombocytopenia  have been reported.  In heavily 
pretreated patients  with aggressive lymph oma, the inciden ce of grade  3 anemia,  neutropenia,  and 
thrombocyt openia was reported  to be 11%,  16%,  and 30%,  respectively. Serious,  suspected drug- 
related  hemorrhages  have been exceptional.  Nevertheless,  Everolimus  should  be considered as 
predisposi ng patients  to hemorrhage,  potentially  fatal, should  they develop severe drug-related 
thrombocyt openia.  
 
Discrete,  reversible cha nges  in liver enzymes  have  been  found  to occur  in numerous  patients  during 
treatment  with Everolim us in oncology clinical stu dies and in a study  in rheumatoid arthritis.  In 
oncology  studies,  these  changes  may be evident only in patients  witho ut severe underlying  morbidity. 
The increase in aspartate  transaminase (AST)  and alanine transaminase (ALT)  generally  appears 
after 4 weeks  of treatment.  In all but a few cases it does not exceed grade  1 (≤2.5 x UL N). Similarly, 
mild increas es in alkaline  phosphatas es can coexist. Spontaneous  corrections  or intermittent 
correction w ith continu ed treatment  can occur.  Serum  bilirub in is not increased.  In studies  of patients 
with advanced cancers,  clinic ally relevant  changes  in liver enzymes  have been  invariably  associated 
with the prese nce of liver metastases  and/or  progression of the underlying  cancer.  
 
Renal  failure has been  reported  in 5 suspected cases to date. One patient  with no alternative 
explanation made  a complete recovery following  study  drug adjustment  and no treatment/therapy  for 
the event.  The rest of the patients  had concurr ent morbidities,  which  might  have contributed to the 
reported  events. 
 
Hypophosphatemia,  hypomagnesemia,  hypona tremia,  and hypocalcemia have  been  reported  as 
serious  adverse reacti ons. Electrol ytes should be monitored  in patients  treated  with Everolimus.  
More  detailed information regarding Everolimus  reported suspected toxicities  and individual  cases  is 
provided in the [Investigator’s  Brochure]. 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  47 of 62  
  
 
 
12.0CRITERIA  FOR  THERAP EUTIC RESPONSE/OUTCOME ASSESSMENT  
 
Complete response (CR) is defined  as no evidence of disease (by cytology  and cystoscopy). 
Progression is defined as the development  of invasion  or metastasis. If the patient  develops  a 
recurrence,  they will be considered having  failed treatment.  Patients  will also be considered  having 
failed  treatment  if there is no respo nse to treatment  after two cycles. 
 
 
Patients  will receive  cystoscopy and cytology every 3 months.  If a sus picious or positive cystoscop y 
or cytology  is found,  then a TUR will be performed no later than 4 weeks  from the suspicious/ positive  
test to determine presence  or absence of disease.  For purposes  of the primary  endpoint,  patients 
demonstrating a CR at 11 months  will un dergo cystoscopy and cytology  (and if suspicious, t hen a 
TUR)  between 11 and 13 months.  
 
 
13.0CRITERIA FOR  REMOVAL  FROM STUDY  
 
If at any time the patient  develops  progressive disease he/she will be taken  off study  and referred for 
alternative therapy.  
 
If at any time the patient  develops  unacceptable toxicity  he/she  will be re moved from study. 
 
If at any point  a patient  develops  any grade  4 toxicity  suspected to be related to gemcitabine,  the 
patient  will be taken  off study. 
 
If a patient  requires  a dose delay  from Everoli mus of >21 days from the intended day of the next 
scheduled d ose, then the patient  must be disco ntinued from the study. 
If the patient  requires  a dose delay  from gemcit abine of >14 days, the patient  will be taken  off study. 
If at anytime  the patient  is found  to be ineligib le for the protocol  as desig nated in the section on 
Criteria  for Patient/Subject  Eligib ility (i.e., a change in diagn osis), the patient will be removed from 
the study.  
 
Patients  who are removed from study  due to withdrawal  of consent,  lost to follow -up, or 
administrat ive problems  should not be consider ed unevaluable and will be replaced.  
 
 
 
14.0BIOS TATISTI CS 
 
Basis  for sample size 
 
Phase  I: Patients  will be accrued in the standard 3+3 fashion such that the MTD is the dose level at 
which  no more than 1 out of 6 patients experience DLT.  This portion will accrue  between 2 and 18 
patients.  
 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  48 of 62  
 Phase  II: The purpose  of this phase  of the study  is to assess the efficacy of gemcitabine plus 
Everolimus  in patients  with BCG-refractory  disease.  The primary  endpoint  will be the proportion of 
patients  who are disease- free at 1 year following start of therapy.  
 
Historically,  only about  10% of patie nts in this sett ing will be disease- free 1 year following therapy, 
therefore a 1- year disease -free rate of 10% would be consi dered not promising,  while  a 30% rate 
would be considered prom ising.  We have chosen  a single -stage design  and set the type I (falsely 
accepting a non-promising  therapy)  and type II error  (falsely  rejecting a p romising  therapy)  rates  at 
0.05 and 0.10, respectiv ely. This portion of the study will enroll  33 patien ts (6 can be carried  over 
from the MTD cohort  of the phase I p ortion).  If there are 7 or more  who are disease-fr ee at 1 year, 
the treatment  will be de clared  effec tive and worthy  of further  testing.  
 
In order  to confirm  the safety  of the regimen,  patients  will con tinuously  be monitored  for excessive 
toxicity  and early stopp ing rules  for toxicity  will be em ployed.  Unaccept able toxicity  is defined  as any 
grade 3 or higher  local toxicity  including hematuria,  urgency,  and frequency. Stopping rules  and the 
corresponding power  calculations ar e provided in the table below.  
 
Table  14-1 
Nu m ber of  toxicities n eeded to  
stop the study True probab ility of toxicity in 
the po pulations  Pr ob ability of study 
comp letion ( based on 
projection)  
1 in the first  7 pati ents 
 
2 in the first  16 patients  
 
3 in the first  28 patients  
 
4 in al l 33 patients 0.05 0.91 
0.11 0.54 
0.20 0.11 
 
 
Secondary  endpoints  
 
a)  To determine  the CR rate (by cytology and cystoscopy) in patients  receiving Everol imus in 
combination with intravesical gemci tabine.  We will ca lculate  the proporti on of patients  who 
demonstrate CR at any time within  the year following start of therapy,  with a 95% confidence 
interval.  With 33 patient s, we will be able to estimate  this proportion within +/- 18%.  
 
b)  To determine  the survival of patients treated  with Everolim us in combi nation with intravesical 
gemcitabine.  Overall  survival following  start of therapy  will be estimated using Kaplan- Meier 
methods.  
 
c)  To evaluate for activated mTOR  pathway  markers  as well as PTEN  status  and AKT 
activation in all pretreatment  and analysis  of posttreatment  specimens  when  availabl e. These 
analyses  will be descript ive in nature and will be used to generate  hypotheses  for future 
studies.  mTOR and PTEN status  will be summarized descriptively,  overall  and separately  for 
those  with and without  a CR. 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  49 of 62  
 Patients  removed  from protocol  therapy for reasons  other  than disease progression,  death,  or 
toxicity  prior to one year will not be evaluable for the primary  end-point  and will be replaced. 
Ho wever,  these patients  may still be evaluable for the second ary end-points.  
 
 
 
15.0 RESE ARCH PART ICIPAN T  REGISTR AT ION AND RANDOMIZ ATION  PROCEDURES  
 
15.1Research  Participant  Re gistration  
Confirm  eligibility  as defined in the section entitled Criteria  for Patient/Subject  Eligibility. 
Obtain  written  informed  consent,  by following pr ocedures  defined in section entitled  Informed  
Consent  Procedures.  
 
All participa nts must  be registered th rough  the Protocol  Participant  Regis tration (PPR)  Office  at 
Memorial  Sloan-Kettering  Cancer  Center.  PPR is available Monday  through Friday  from 8:30am  – 
5:30pm  at 646-735-8000.  The PPR fax numbers  are (646)  735-0008 and (646)  735-0003. 
Registratio ns can be phoned  in or faxed. The completed sig nature page  of the informed consent 
form,  the completed sig nature page  of the Research  Author ization  and a completed Eligibility 
Checklist  must be faxed  to PPR.  
 
During  the registration p rocess  registering  individuals  will be required to answer  specific  eligibility 
questions  and provide  the following  information:  
 
Registering  Individual  [Last, First Name] 
Research Authorization  [Date] 
MSKCC  IRB Protocol#  
Attending of Record (if applicable )[Last, First Name] 
Consenting Professional  [Last, First Name]  
Informed Co nsent  Date 
Participant’s  Full Name  [Last, First Name] 
Participant  MRN  
 
 
 
15.2Randomization  
 
Not applica ble 
 
16.0DATA  MANAG EME NT ISSU ES 
 
A Research Study  Assistant (RSA)  will be assign ed to the study. The responsibi lities of the RSA 
include  project  compli ance, data co llection,  abstraction and entry,  data reporting,  regulatory 
monitoring,  problem  resolution and prioritiza tion, and coordination of the activities  of the protocol 
study  team.  
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  50 of 62  
 The data collected for this study  will be entered  into a secure database.  Source documentation will 
be available to support  the computerized patient  record.  
 
16.1Quality  Assurance  
 
 
 
Monthly  registration  reports will be ge nerated to monitor  patient  accruals and completeness  of 
registration data.  Routine  data quality reports  will be generated  to assess missing  data and 
incons istencies.  Accrual  rates  and extent  and accuracy  of evaluations  and follow -up will be 
monitored periodical ly throughout  the study  period  and potential problem s will be brought  to the 
attention  of the study  team  for discussion and action. Random -sample d ata quality  and protocol 
compliance audits  will be conducted by the study  team  at a minim um of two times  per year,  more 
frequently  if indicated.  
 
16.2Data  and Safety  Monitoring  
 
 
The Data and Safety  Monitoring (DSM) Plans  at Memorial  Sloan-Kettering Cancer  Center  were 
approved by the National  Cancer  Institute  in September  2001.  The plans  address  the new policies 
set forth by the NCI in the document  entitled  “Policy  of the National  Canc er Institute  for Data and 
Safety  Moni toring  of Clinical Trials,”  which  can be found  at: 
http://cance rtrials.nci.nih. gov/researchers/dsm/index.htm l. The DSM  Plans at MSKCC  were 
established and are monitored  by the Office  of Clinic al Research.  The MSKCC  Data and Safety  
Monitoring Plans  can be found on the MSKCC  Intranet  at: http://m skweb2. mskcc.o rg /irb/index .htm 
 
 
There are several  different  mechanisms  by which  clinical  trials are monitored  for data,  safety  and 
quality.  There are institu tional processes  in place  for quality  assurance (e.g., protocol  monitoring, 
compliance and data verification  audits,  therapeu tic response,  and staff education on clinic al 
research QA) and departmental  procedures  for quality  control, plus there are two institution al 
committees  that are responsible for monitoring  the activities  of our clinical  trials programs.  The 
committees,  Data and Safety  Monitoring Commit tee (DSMC) for Phase I and II clinical trials and the 
Data  and Safety  Monitoring  Board (DSMB) for Phase III clinical trials,  report to the Center’s 
Research  Council  and Institution al Review  Board. 
 
During  the protocol  development  and review  process,  each pr otocol  will be assessed for its level of 
risk and degree of monitoring requi red. Every  type of protocol  (e.g.,  NIH sponsored,  in-house 
sponsored,  industrial  sponsored,  NCI cooperat ive group,  etc.) will be addressed and the monitoring 
procedures  will be estab lished  at the time of protocol  activat ion. 
 
17.0PRO TECTION OF HUM AN SUBJECTS  
 
17.1Pr
ivacy 
 
MSKCC’s  Privacy Office  may allow  the use and disclosure  of protected  health information pur su ant 
to a completed and signed Research Authorization form.  The use and disclosure of protected he alth 
information will be limited to the individuals  described  in the Research Authorization form.  A 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  51 of 62  
 Research Authorization form must  be completed by the Principal  Investig ator and approved by the 
IRB and Privacy Board (IRB/PB).  
17.2Serious  Adverse  Event  (SAE)  Reporting 
 
Any SAE must  be reported to the IRB/PB as soon as possible but no later than 5 cale ndar days.  The 
IRB/PB requires a Clinical Research Database (CRDB)  SAE report  be submitted  electronically  to the 
SAE Office  at sae@ mskcc.org  containing the following  information:  
 
 
Fields  populated from CRDB:  
 
• Subject’s  name (generate the report  with only initials  if it will be sent outside of 
MSK CC)  
• Medical  record  number  
• Disease/his tology  (if applicable)  
• Protocol  number  and title 
 
Data  needing to be entered: 
 
• The date the adverse event  occurred 
• The adverse event  
• Relationship  of the adverse event  to the treatment  (drug,  device,  or intervention)  
• If the AE was expected  
• The severity  of the AE 
• The intervention  
• Detailed  text that includes the following  
o A explanation of how the AE was handled  
o A descripti on of the subject’s  condition  
o Indication if the subject  remains  on the study  
o If an amendment  will need to be made  to the protocol  and/or consent  form. 
The PI’s signature and the date it was signed are required on the completed report.  
For IND/ IDE  protocols:  
The CRDB  AE report  should  be completed as above and the FDA assigned IND/ IDE  number 
written  at the top of the report.  The report  will be forwarded to the FDA by the Institu tional 
SAE Manag er through the IND Office.  
 
17.2. 1Serious  Adverse  Event  (SAE)  Reporting  to Novartis  
 
The Princi pal Investigat or has the obligation  to report  all serious  adverse events  to the IRB, and 
Novartis  Pharmaceuticals  Clinical  Safety and Epidemiology  Department  (CS&E).  
 
All events  must  be reported,  by Fax (888-299-4565)  to Novartis  Pharmaceuticals  CS&E 
Department  within  24 hours  of learning  of its occurrence .  This includes serious,  related,  labeled 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  52 of 62  
 (expected)  and serious,  related,  unlabeled (unexpected)  adverse experiences.  All deaths during 
treatment  or within  30 days following  completi on of active protocol  therapy must be reported within  5 
working days. 
 
Any serious  adverse  event occurring after the patient  has provided informed consent  and until 4 
weeks  after the patient  has stopped  study  participation must  be reported.  This includes the period in 
which  the study protocol  interferes  with the standard medical  treatment  given  to a patient  (e.g. 
treatment  withdrawal  during  washout  period,  change in treatment  to a fixed dose  of concomitant 
medication).  
 
Serious  adverse  events  occurring more  than 4 weeks  after study discontinuation need only be 
reported  if a relationship to the Novartis study  drug (or therapy)  is suspected.  
 
For Comparator  Drugs/Secondary  Suspects  (Concomitant  Medications),  all serious adverse 
experiences  will be forwarded to the product  manufacturer  by the investigator.  
 
Any pregn ancy that occurs  during  study partici pation  should  be reported.  To ensure patient  safety, 
each  pregna ncy must  also be reported to Novartis  within  24 hours of learning of its occurrence.  The 
pregnancy  should  be followed up to determine  outcome,  including  spont aneous  or voluntary 
termination,  details  of birth, and the presence or absence of any birth defects,  conge nital 
abnormalities,  or maternal  and newborn complications.  
 
 
 
18.0INFORMED  CONSENT  PROCEDURES  
 
Patients  will be required to sign a statement  of informed consent  which  meets  the 
requirements  of code  of Federal  Regulations  (Federal  Regis ter Vol. 46, No. 17, Jan. 27, 1981,  part 
50) and the IRB of this center.  
 
 
Consent  Process: The consenting professional  will review  the rationale for the treatment  program 
with the patient.  The discussion will review  the alternatives  available,  including supp ortive care as 
appropriate,  the potenti al benefits  of this program,  the risks and the probability  of their occurrenc e, 
and the procedures  to minimize  these risks. T he provisions  available  to ensure  medical  intervent ion 
should  an adverse event occur  will a lso be revie wed. Whether  the risks are reasona ble in relati on to 
the anticipat ed benefits,  incentives, costs that will or may be incurred as a result  of participation in 
the study, and efforts  to maintain the confidenti ality of research participan ts will also be discussed. 
 
At the time of registrati on, the eligibil ity checklist will be reviewed,  verified,  and signed. 
MSKCC  Physi cians Eligible to Register  Patients: Final  informed consent  may be obtained by the 
consenting professionals  listed  on the protocol  face sheet.  
 
 
Documentation of Informed Consent:  The informed consent  will be signed by the patient  and 
consenting professional  in triplicate.  A signed  original copy of the consent form will be given  to the 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  53 of 62  
 patient.  The second  original will be pl aced  in the medical  record,  and the third origin al will be kept in 
the research file. 
 
18.1Re search  Authorization 
 
Procedures  for obtaining Research Authorization:  Before  any protocol -specific proced ures are 
carried  out, investigators  and/or  designated staff will fully explain  the detai ls of the protocol,  study 
procedures,  and the aspects of patient privacy concer ning re search sp ecific information.  In addition 
to signing  the IRB Informed Consent,  all patien ts must sign the Research Authoriz ation component  
of the informed  consent  form. The Research Authorization requires  a separate set of signatures  from 
the patient.  The original  signed  documents will become part of the patien t’s medical  record,  and 
each  patient  will receive a copy of the signed  documents. 
 
19.0 REFERENCES 
 
1, Boulay A  and Lane HA.  The mammalian target of  rapamycin kinase and tumor 
growth inhibition. 2007 Recent Results Cancer Res 172: 99-124.  
 
2. Bjornsti MA  and Houghton PJ.  The TOR  pathway: a target for  cancer therapy. 2004  
Nat Rev Cancer 4:  335-48. 
 
3. Wullschleger S,  Loewith R and Hall MN. TOR  signaling in growth and metabolism.  
2006 Cell 124: 471-84.  
 
4. Manning BD and Can tley LC. AKT/PKB signaling: navigating dow nstream.  2007 Cell  
129: 1261-74.  
 
5. Wang L,  Harris TE,  Roth RA and Law rence JC, Jr.  PRAS40 regulates mTO RC1 
kinase activity by functioning as a direct  inhibitor of  substrate binding. 2007 J Biol 
Chem 282: 20036- 44. 
 
6. Witzig TE,  Geyer SM,  Ghobrial I,  Inwards  DJ, Fonseca R, Kurtin P,  Ansell SM,  Luyun 
R, Flynn PJ,  Morton RF,  Dakhil SR,  Gross H and Kauf mann SH.  Phase II  trial of 
single- agent temsirolimus (CCI -779) for  relapsed mantle cell lym phoma. 2005 J Clin 
Oncol 23: 5347-56.  
 
7. Zitzmann K , De Toni EN,  Brand S,  Goke  B, Meinecke J,  Spottl G,  Meyer HH and 
Auernham mer CJ. The novel mTOR  inhibitor RAD001 (everolimus ) induces 
antiproliferative effects  in human panc reatic neuroendocrine tumor cells. 2007  
Neuroendocrinology 85: 54-60.  
 
8. Zeng Z,  Sarbassov dos D, Samudio IJ,  Yee KW,  Munsell MF,  Ellen Jackson C, Giles 
FJ, Sabatini DM, Andreeff M and Konopleva M.  Rapamycin derivatives reduce 
mTORC2 signaling and inhibit AKT  activation in AML.  2007 Blood 109: 3509- 12. 
 
9. Ikezoe T,  Nishio ka C, Bandobashi K,  Yang Y, Kuwayama Y,  Adachi Y,  Takeuchi T, 
Koeffler HP and Taguc hi H. Longi tudinal i nhibition of  PI3K/Akt/mTOR  signaling by 
LY294002 and rapamycin induc es growth arrest of  adult T -cell leukemia cells. 2007  
Leuk Res 31: 673-82.  
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  54 of 62  
 10. Wanner K,  Hipp S,  Oelsner M,  Rings hausen I,  Bogner C, Peschel C and Decker  T. 
Mammalian target of  rapamycin inhibition induc es cell cycle arrest in diffuse large B 
cell lymphoma (DLBCL) cells and sensiti ses DLBCL cells to rituximab. 2006 Br J 
Haematol 134: 475-84.  
 
11. Tuncyurek P,  Mayer JM,  Klug F,  Dillmann S, Henne-Bruns D, Kell er F and Stracke S.  
Everolimus  and mycophenolate mofetil sensi tize human pancreatic cancer cells to 
gemcitabine in vitro:  a novel adjunct to standard chemotherapy? 2007 Eur Surg Res  
39: 380-7.  
 
12. Treeck O,  Wackwitz B,  Haus U and Ortmann O. Effects  of a combined treatment with 
mTOR  inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of  human 
cancer cells. 2006 Gynecol Oncol 102: 292-9.  
 
13. Mabuchi S,  Altomare DA,  Cheung M,  Zhang L,  Poulikakos PI,  Hensley HH, Schilder 
RJ, Ozols RF and Testa JR. RAD001 inhibits  human ovarian canc er cell proli feration, 
enhances cisplatin- induced apop tosis, and prolongs survival in an ovarian cancer 
model. 200 7 Clin Can cer Res 13: 4261-70.  
 
14. Sieghart W,  Fuereder T,  Schmid K,  Cejka D, Werzo wa J, Wrba F,  Wang X, Gruber D, 
Rasoul -Rockenschaub S,  Peck -Radosa vljevic M and Wacheck V.  Mammalian target 
of rapamycin pathway activity in hepatoc ellular carcin omas of  patients undergoing 
liver transplantation. 2007 Transplantation 83: 425-32.  
 
15. Haritunians  T, Mori A,  O'Kelly  J, Luong QT,  Giles FJ  and Koeffler HP.  
Antiproliferative activity of  RAD001 (ev erolimus) as a single agent and combined with 
other agents in mantle cell l ymphoma. 2007 Leukemia 21: 333- 9. 
 
16. Lane H, Tanaka C and Kov arik J.  Preclinical and clinical pharmacokinetic / 
pharmacodynamic (PK/PD)  modeling to help define an optimal biological dos e for the 
oral mTOR  inhibitor, RAD001,  in oncol ogy. 2003 J  Clin Oncol  22: 237A.  
 
17. Tabernero J,  Rojo F  and Casado Eea. A  phase 1 study with tumor molecular 
pharmacodynamic evaluation of  dose and schedule of  the oral mTOR  inhibitor 
everlolimus (RAD001) in patients with advan ced solid t umors.  2005 J Clin Oncol 23:  
3007.  
 
18. Motzer RJ, Escudier B, Oudard S,  Hutson TE,  Porta C, Bracarda S, Grunwald V, 
Thompson JA,  Figlin RA,  Hollaender N, U rbanowitz G,  Berg WJ,  Kay A, Lebwohl D 
and Ravaud A.  Efficacy  of everolimus  in advanced ren al cell carcinoma: a double- 
blind, randomised, placebo-controlled phase III trial. 2008 Lancet 372: 449-56.  
 
19. Kay A,  Motzer R, Figlin R, Escudier B,  Oudard S,  Porta C, Hutson T,  Bracarda S, 
Hollaender N, Urbanowitz G  and Ravaud A.  Updated data from a phase III 
randomized trial of  everolimus (RAD001) versus PBO  in metastatic renal cell 
carcinoma (mRCC). Abstract  278. Geni tourinary Canc ers Symposium. Orlando, 
Florida. Feb.  26-28, 2009.  
 
20. Hertel LW,  Boder GB,  Kroin JS,  Rinzel SM,  Poore GA,  Todd GC and Grindey GB.  
Evaluation of  the antitumor activity of  gemcitabine ( 2',2'-difluoro-2' -deoxycytidine).  
1990 Canc er Res 50: 4417- 22. 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  55 of 62  
 21. Burris HA,  3rd, Moore MJ,  Ander sen J,  Green MR, Rothenberg ML,  Modiano MR, 
Cripps MC, Portenoy RK,  Storniolo AM,  Tarassoff  P, N elson R, Dorr FA,  Stephens 
CD and Von Hoff  DD. Improvements in survival and clinical benef it with gemcitabine 
as first -line therapy for  patients with advanced pancreas  cancer: a randomized trial.  
1997 J Clin Oncol 15: 2403-13.  
 
22. Moore MJ,  Tannock IF,  Ernst DS, Huan S  and Murray N. Gemcitabi ne: a prom ising 
new agent in the treatment of  advanced urothelial canc er. 1997 J Clin Oncol 15:  
3441- 5. 
 
23. Stadler WM,  Kuzel T,  Roth B,  Raghavan D and Dorr FA.  Phase II  study of  single- 
agent gemcitabine in previously  untreated patients  with metastatic  urothelial cancer.  
1997 J Clin Oncol 15: 3394-8.  
 
24. Lorusso V,  Pollera CF,  Antimi M,  Lupori ni G, Gridelli C, Frassineti GL,  Oliva C, Pacini 
M and De Lena M.  A phase II  study of  gemci tabine in patients with transitional cell 
carcinoma of  the urinary tract  previously treated with platinum. Italian Co-operative 
Group on Bladder Cancer. 1998 Eur J Cancer 34: 1208-12.  
 
25. von der Maase H, Hansen SW,  Roberts JT,  Dogliotti L,  Oliver T,  Mo ore  MJ, Bodrogi 
I, Albers P,  Knuth A,  Lippert CM, Kerbrat P,  Sanchez Rovira P,  Wersall P,  Cleall SP, 
Roychowdhury DF,  Tomlin I,  Visseren-Grul CM and Conte PF.  Gemcitabine and 
cisplatin versus methotrexate, vinblastine,  doxorubicin, and cisplatin in advanced or 
metastatic bladder cancer: results of  a large, randomized, multi national, multicenter, 
phase III  study.  2000 J Clin Oncol 18: 3068- 77. 
 
26. Dalbagni G, Russo P,  Sheinfeld J, Mazumdar M,  Tong W,  Rabbani F,  Donat MS, 
Herr HW,  Sogani  P, dePalma D and Bajor in D. Phase I  trial of  intravesical 
gemcitabine in bacillus Calmette- Guerin-refractory transition al-cell  carcinoma of  the 
bladder. 2002 J Clin Oncol 20: 3193- 8. 
 
27. Dalbagni G, Russo P,  Bochner B,  Ben-Porat L,  Sheinf eld J,  Sogani P,  Donat MS, 
Herr HW and Bajorin D. Phase II  trial of  intravesical gemcitabine in bacille Calmette- 
Guerin-refractory transition al cell carcinoma of  the bla dder. 2006 J Clin Oncol 24:  
2729- 34. 
 
28. Laufer M,  Ramalingam S,  Schoenberg MP,  Haisfield-Wolf ME,  Zuhows ki EG, 
Trueheart IN, Eisenberger MA,  Nativ O  and Egorin  MJ. Intravesical gemcitabi ne 
therapy for  superficial transitional c ell carcinoma of  the bladder: a phase I  and 
pharmacokinetic study.  2003 J Clin Oncol 21: 697-703.  
 
29. De Berardinis E,  Antonini G,  Peters GJ,  Loves W J, Van der Born K,  Codacci -Pisanelli 
G and Di Silverio F.  Intravesical administr ation of  gemcitabine in superficial bladder 
cancer: a phase I  study with pharmacodynamic evaluation. 2004 BJU Int  93: 491- 4. 
 
30. Jemal A,  Siegel R, Ward E,  Hao Y,  Xu J and Thun MJ.  Cancer statistics,  2009. 2009  
CA Cancer  J Clin 59: 225- 49. 
 
31. Soloway MS.  Overview of  treatment of  superficial bladder cancer. 1985 Urology 26:  
18-26.  
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  56 of 62  
 32. Surveillanc e, initial as sessment, and subse quent progress  of patients with superficial 
bladder cancer in a prospective longi tudinal study.  National Bladder Cancer 
Collaborative Group A  (NBCCGA). 1977 Cancer Res 37: 2907- 10. 
 
33. Herr HW,  Jakse G  and Sheinfeld J.  The T1 bladder tumor.  1990 Semin Urol 8:  254- 
61. 
 
34. Milowsky MI,  Tickoo  SK, Ga llagher  DJ, Bajorin DF a nd Reuter VE.  HIF and mTOR 
pathways in invasive urothelial carc inoma: A  study with potential therapeutic 
implications. Abstract  292. Genitourinary Cancers Symposium.  San Francisco, 
California. Feb.  14-17, 2008.  
 
35. Neshat M,  Mellinghoff I,  Tran C, St iles B, Thomas G,  Petersen R, Frost  P, Gibbons 
JJ, Wu H and Sawyers CL. Enhanced sensi tivity of  PTEN -deficient tumors to 
inhibition of FRAP/mTOR.  2001 Proc Natl Acad Sci USA 98: 10314- 9. 
 
36. Yilmaz OH,  Valdez R, Theisen BK,  Guo W,  Ferguson DO,  Wu H and Morrison SJ.  
Pten dependence distinguishes haematopoietic stem  cells f rom leukaemia-initiating 
cells.  2006 Nature 441:  475-82.  
 
37. Podsypanina K,  Lee RT,  Politis C, Hennessy I,  Crane A,  Puc J,  Neshat M,  Wang H, 
Yang L,  Gibbons J,  Frost  P, Dreisbach V,  Blenis J,  Gaciong Z,  Fisher P,  Sawyers C, 
Hedrick -Ellenson L and Parsons R. An inhibitor of  mTOR  reduces neoplasia and 
normalizes p70/S6 kinase activity  in Pten+/- mice. 2001 Proc Natl Acad Sci USA 98:  
10320-5.  
 
38. Majumder PK,  Febbo PG,  Bikoff  R, Berger R, Xue Q,  McMahon LM,  Manola J, 
Brugarolas J,  McDonnell TJ,  Golub TR,  Loda M,  Lane HA and Sellers WR.  mTOR 
inhibition reverses Akt -dependent prostate intraepithelial neoplasia through 
regulation of  apoptotic  and HIF -1-dependent pathways. 2004 Nat Med 10: 594-601.  
 
39. Cloughesy TF,  Yoshimoto  K, Nghiemphu P,  Brown K,  Dang J,  Zhu S,  Hsueh T,  Chen 
Y, Wang W,  Youngkin D, Liau L,  Martin N, Becker  D, Berg sneider M,  Lai A,  Green R, 
Oglesby T,  Koleto M,  Trent  J, Horvath S,  Mischel PS,  Mellinghoff IK  and Sawyers CL. 
Antitumor activity of  rapamycin in a Phase I  trial for  patients with recurrent PTEN - 
deficient glioblastoma. .  2008 PLoS Med 5:  e8. 
 
40. Atkins MB,  Hidalgo M,  Stadler  W M, Logan TF,  Dutcher JP,  Hudes GR,  Park Y, Liou 
SH, Marshall B,  Boni JP,  Dukart G  and Sherman ML.  Randomized phase II  study of 
multiple dose levels of  CCI-779, a novel  mammalian target of  rapamycin kinase 
inhibitor, in patients with advanced refract ory renal cell carcinoma. 2004 J  Clin Oncol  
22: 909-18.  
 
41. Loomba R, Rowley A,  Wesley R, Liang TJ, Hoofnagle JH, Pucino F  and Csak o G. 
Systematic review: the effect  of prevent ive lamivudine on hepatitis B  reactivation 
during chemotherapy. 2008 Ann  Intern Med 148: 519-28.  
 
42. Krishna G, Moton A,  Ma L,  Savant I,  Martinho M,  Seiberling M and McLeod J.  Effects 
of oral posaconazole on the pharmacokinetic properties of  oral and intravenous 
midazolam:  A phase I,  randomized, open-label, crossover study in healthy  
volunteers. 2009 Clin Ther 31: 286-98.  
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  57 of 62  
  
 
 
20.0 APPENDICES  
 
Appendix  1: Everolimus  (RAD001)  Continuous  Cycle  Schedule Treatment  Log (5mg  every  other 
day) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended:  1/11/11  
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)  
Page  58 of 62  
 Patient Nam e:   Patient MRN :   
 
Protocol 10-165: Phase I/II  Study of Evero limu s  and Intravesical Gemcitabine  in BCG - 
Refracto ry Primary  or Seconda ry Carcinoma In  Situ of the Bl adder  
EVEROLIMUS  (RAD001) CONTINUOUS CYCLE SCHEDULE  TREATMENT  LOG 
Pla ce a  che ck in the box  next to the d a te you t ak e t his  medic ation. 
Please bring  this she et to your stu dy docto r's off ice  on ea ch visit  
Cycle:     
Da te Day Time  Trea t ment Dose  Questions  for Study  Doctor/Nur se 
  
1  Eve rolimus      
5 mg   
  
2     
  
3  Eve rolimus      
  
4     
  
5  Eve rolimus      
  
6     
  
7  Eve rolimus      
  
8     
  
9  Eve rolimus      
  
10     
  
11  Eve rolimus      
  
12     
  
13  Eve rolimus      
  
14     
  
15  Eve rolimus      
  
16     
  
17  Eve rolimus      
  
18     
  
19  Eve rolimus      
  
20     
 
 
Amended:  1/11/11  
Page  59 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
   
21  Eve rolimus      
  
22     
  
23  Eve rolimus      
  
24     
  
25  Eve rolimus      
  
26     
  
27  Eve rolimus      
  
28     
MD/RN  
Signature:     
Date:     
Tablets  Remaining: _   
 
 
Comments:_   
 
 
 
 
 
Appendix  2: Everolimus  (RAD001)  Continuous  Cycle  Schedule Treatment  Log (5 mg every  day)  
 
Patient Nam e   Patient MRN :   
 
Protocol 10-165: Phase I/II  Study of Evero limu s  and Intravesical Gemcitabine  in BCG - 
Refracto ry Primary  or Seconda ry Carcinoma In  Situ of the Bl adder  
EVEROLIMUS  (RAD001) CONTINUOUS CYCLE SCHEDULE  TREATMENT  LOG 
Pla ce a  che ck in the box  next to the d a te you t ak e t his  medic ation. 
Please bring  this she et to your stu dy docto r's off ice  on ea ch visit  
Cycle:     
Da te Day Time  Trea t ment Dose  Questions  for Study  Doctor/Nur se 
  
1  Eve rolimus     
5 mg   
  
2  Eve rolimus      
  
3  Eve rolimus      
  
4  Eve rolimus      
  
5  Eve rolimus      
  
6  Eve rolimus      
  
7  Eve rolimus      
 
Amended:  1/11/11  
Page  60 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
   
8  Eve rolimus      
  
9  Eve rolimus      
  
10  Eve rolimus      
  
11  Eve rolimus      
  
12  Eve rolimus      
  
13  Eve rolimus      
  
14  Eve rolimus      
  
15  Eve rolimus      
  
16  Eve rolimus      
  
17  Eve rolimus      
  
18  Eve rolimus      
  
19  Eve rolimus      
  
20  Eve rolimus      
  
21  Eve rolimus      
  
22  Eve rolimus      
  
23  Eve rolimus      
  
24  Eve rolimus      
  
25  Eve rolimus      
  
26  Eve rolimus      
  
27  Eve rolimus      
  
28  Eve rolimus      
MD/RN  
Signature:     
Date_    
Tablets  Remaining   
 
 
Comments:_   
 
 
Appendix  3: Everolimus  (RAD001)  Continuous  Cycle  Schedule Treatment  Log (10 mg every  day) 
 
Amended:  1/11/11  
Page  61 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
 Patient Nam e:   Patient MRN :   
 
Protocol 10-165: Phase I/II  Study of Evero limu s  and Intravesical Gemcitabine  in BCG - 
Refracto ry Primary  or Seconda ry Carcinoma In  Situ of the Bl adder  
EVEROLIMUS  (RAD001) CONTINUOUS CYCLE SCHEDULE  TREATMENT  LOG 
Pla ce a  che ck in the box  next to the da te you ta ke  this 
medication.  Please bring  this she et to your stu dy 
doctor's office on ea ch visit  
 
Cycle:     
Da te Day Time  Trea t ment Dose  Questions  for Study  Doctor/Nur se 
  
1  Eve rolimus     
10 mg   
  
2  Eve rolimus      
  
3  Everolimus       
  
4  Eve rolimus      
  
5  Eve rolimus      
  
6  Eve rolimus      
  
7  Eve rolimus      
  
8  Eve rolimus      
  
9  Eve rolimus      
  
10  Eve rolimus      
  
11  Eve rolimus      
  
12  Eve rolimus      
  
13  Eve rolimus      
  
14  Eve rolimus      
  
15  Eve rolimus      
  
16  Eve rolimus      
  
17  Eve rolimus      
  
18  Eve rolimus      
  
19  Eve rolimus      
  
20  Eve rolimus      
 
Amended:  1/11/11  
Page  62 of 62 
ME MOR IAL  SLOAN -KETTER ING  CANC ER CEN TER 
IRB PROTOCOL  
IRB#:  10-165A(1)   
   
21  Eve rolimus      
  
22  Eve rolimus      
  
23  Everolimus       
  
24  Eve rolimus      
  
25  Eve rolimus      
  
26  Eve rolimus      
  
27  Eve rolimus      
  
28  Eve rolimus      
MD/RN  
Signature:     
Date_   Tablets  
Rema ining   
 
Comments:_   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amended:  1/11/11  